

Granted Pharmaceutical Patents in Egypt

TAHIR AMIN

DECEMBER 2011

WWW.I-MAK.ORG

CONTENTS

Methodology

Summary of Granted Pharmaceutical Patents in Egypt

Granted Pharmaceutical Patents in Egypt – Full Report

Methodology

Abstracts for granted pharmaceutical patents in Egypt for the period 1 January 2005 – 31 December 2010 were obtained from the Egyptian Patent Office by the Egyptian Initiative for Personal Rights (EIPR).¹

The abstracts provided the following basic bibliographic data:

- Applicant name(s)
- Inventor(s)
- Priority numbers and dates
- Legal representative
- Title of the claimed invention
- Start and end of the period of protection for the patent
- Abstract of the claimed invention
- Application number and date
- Publication date
- Granted patent number and publication date

The granted patent number in Egypt was then searched using the European Office (esp@cenet) and Thomson Innovation databases. As the complete patent document for each granted patent in Egypt is not publicly available on any database, the specification and claims of the corresponding U.S., European or international patent (PCT) and related patents in the INPADOC patent family were studied to establish the potential subject matter and product covered in Egypt.

While conducting the above search against each granted Egyptian patent, the corresponding U.S. patent(s) and U.S. patent(s) in the INPADOC patent family were checked against patents listed for originator companies on the United States Food and Drug Administration's Orange Book (US FDA Orange Book). This was to establish whether any of the patents granted in Egypt related to patents listed against pharmaceutical products approved for marketing in the U.S. Where the corresponding U.S. patent(s) and U.S. patent(s) in the INPADOC patent family for a granted Egyptian patent does not appear on the US FDA Orange Book, a note to this effect has been entered for the relevant patent.

It should be noted here that companies are not required to list patents covering a process or method of preparing a compound or formulation on the U.S. FDA Orange Book. As such it was not possible to determine whether any of the granted process patents in Egypt relate to a marketed product as listed on the U.S. FDA Orange Book. Also, only granted patents relating to a marketed product are listed on the U.S. FDA Orange Book. Therefore, pending U.S. patents that may relate to marketed products will not have been identified in this report.

¹ Egypt commenced its pharmaceutical product patent regime under TRIPS on 1 January 2005. This project was conducted in collaboration with Dina Iskander of the Egyptian Initiative for Personal Rights, who is conducting research on the impact of TRIPS on pharmaceutical patenting in Egypt.

Limitations of the Methodology

As is often the case, granted patent claims differ from country to country. As a result, the reliance on corresponding U.S., European or international patent (PCT) and related patents in the INPADOC patent family may not match the final claims that were granted in Egypt and, therefore, not reflect the eventual scope of the subject matter and product covered.

Nevertheless, by studying the available specifications and claims for corresponding patents and the INPADOC patent family, it is possible to obtain a sense of which pharmaceutical products may have patent protection in Egypt. By identifying such patents in this report, it will then be possible to focus efforts and resources on obtaining the complete patent documents and claims for these patents to carry out a more in-depth assessment of pharmaceutical products that are patented in Egypt.

Summary of Granted Pharmaceutical Patents in Egypt

The following table summarises pharmaceutical product patents granted in Egypt that correspond with U.S. patents listed on the U.S FDA Orange Book for originator branded medicines.²

Applicant	Granted Patent Number (Egypt)	Subject Matter/Active Ingredient (generic name/INN)	Brand Name of Marketed Product	Treatment Category
American Home Products	23687	Pharmaceutical composition comprising estrogens conjugated medproxyprogesterone acetate	Prempro	Symptoms of menopause
Schering Corporation	23759	Composition/formulation comprising desloratidine	Clarinet D - 12/24 Hour	Allergic rhinitis
Sanofi	23762	Composition comprising dronedarone	Multaq	Atrial fibrillation
Novo Nordisk	23781	Composition comprising tiagabine	Gabitril	Partial seizures
Eli Lilly & Co	23815	Crystalline dihydrate of olanzapine	Zyprexa	Schizophrenia
Pfizer Products Inc	23816	Compounds covering varenicline	Chantix	Smoking addiction
Pfizer Products Inc	23818	Composition comprising sertraline	Zoloft	Depression and other behavioyral disorders
Pfizer Research and Development Company	23822	Polymorph of elepriptan	Relpax	Migraine headaches
Pfizer Research and Development Company	23826	Dosage form comprising darifenacin	Enablex	Overactive bladder
Glaxo Group Limited	23836	Hemisulfate salt of abacavir	Ziagen	HIV/AIDS
Smithkline Beecham Plc	23934	Formulation comprising paroxetine	Paxil	Social anxiety disorders
Bristol Myers Squibb & Co	23936	Bisulfate salt of atazanavir	Reyataz	HIV/AIDS
Smithkline Beecham Plc	23937	Polymorph of rosiglitazone maleate	Avandaryl	Control of blood sugar in patients with type II diabetes
Laboratoires Fournier SA	23978	Composition comprising fenofibrate	Tricor	Dieting and lowering triglycerides
Pfizer Products Inc	24008	Composition comprising crystalline form of ziprasidone hydrochloride monohydrate	Geodon	Schizophrenia and bi-polar disorders

² Brand names for products marketed in the U.S may be different for the same products marketed in Egypt.


Applicant	Granted Patent Number (Egypt)	Subject Matter/Active Ingredient (generic name/INN)	Brand Name of Marketed Product	Treatment Category
Sanofi-Synthelabo	24015	Polymorphic form of clopidogrel hydrogen sulfate	Plavix	Prevention of strokes and heart attacks
Zeneca Limited	24134	Compounds covering gefitinib	Iressa	Cancer
Pfizer Inc	24135	Composition comprising ziprasidone	Geodon	Schizophrenia
Pfizer Inc	24137	Compounds covering maraviroc	Selzentry	HIV/AIDS
Boehringer Ingelheim Pharma KG	24139	Inhalable powder containing tiotropium	Spiriva	Chronic obstructive pulmonary disease
Boehringer Ingelheim	24142	Crystalline form of tiotropium bromide monohydrate	Spiriva	Chronic obstructive pulmonary disease
American Home Products Corporation	24198	Extended release formulation of venlafaxine hydrochloride	Effexor	Depression
Smithkline Beecham Plc	24199	Method of treatment/use administering rosiglitazone maleate and metformin hydrochloride	Avandamet	Diabetes
Smithkline Beecham Plc	24200	Polymorphic form of rosiglitazone maleate	Avandia	Type II diabetes
H Lundbeck A/S	24206	Crystalline particles of escitalopram oxalate	Lexapro	Depression
Pfizer Products Inc	24228	Tartrate salt of varenicline	Chantix	Smoking addiction
Pfizer Inc	24229	Compounds covering erlotinib	Tarceva	Non-small cell lung cancer
Astra Aktiebolg	24291	S-enantiomer of omeprazole (esomeprazole)	Vimovo	Osteoarthritis
F. Hoffman La Roche	24292	Pegylated interferon conjugates of interferon alpha 2a	Pegasys	Hepatitis C
F. Hoffman La Roche	24294	Formulation comprising saquinavir	Fortovase	HIV/AIDS
Pfizer Inc	24400	Compounds covering maraviroc	Selzentry	HIV/AIDS
Pfizer Inc	24401	Mesylate trihydrate salt of ziprasidone	Geodon	Schizophrenia
Bayer Corporation	24407	Compounds covering sorafenib	Nexavar	Cancer


Granted Pharmaceutical Patents in Egypt (1 January 2005 – 31 December 2010)



	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
1	Astra Aktiebolag	SE 9404466/6 22.12.1994 SE 9502369/3 30.6.1995	19951060 21/12/1995 Pub Date. 12/2006	23683 9.5.2007	20.12.2015	<p><i>Process for the Preparation of Powders for Inhalation and Powders Obtainable Thereby</i></p> <p>A proliposome powder, said powder comprising in a single phase discrete particles of a biologically active component together with a lipid or mixture of lipids having a phase transition temperature of below 37C</p>	<p><i>Patent Type: Product (Composition)</i></p> <p>The patent covers a proliposome proliposome powder (glucocorticosteroids and esterified glucocorticosteroids such as rofleponide palmitate (useful for treating allergic rhinitis and asthma), antiinflammatory drugs, antihistamines, cyclooxygenase inhibitors, leukotriene antagonists, PLA2 inhibitors, PAF antagonists and prophylactics of asthma), said powder comprising in a single phase discrete particles of a biologically active component together with a lipid or mixture of lipids having a phase transition temperature of below 370C.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
2	Smithkline Beecham Plc	GB 9/9600847 16.1.1996	19970046 14.1.1997 Pub Date. 12/2006	23684 9.5.2007	13.1.2017	<i>Pharmaceuticals</i> A pharmaceutical tablet wherein famciclovir is the active ingredient and wherein the percentage of famciclovir by weight in the tablet is 85% or greater.	<i>Patent Type: Product (Formulation)</i> The patent claims an invention for a pharmaceutical tablet wherein famciclovir is the active ingredient and wherein the percentage of famciclovir by weight in the tablet is 85% or greater. The antiviral activity of famciclovir can used to treat infections caused by the different strains of herpesvirus and hepatitis B. The active ingredient famciclovir is no longer under patent and available in generic form. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.
3	Eli Lilly & Co.	US 60/045255 28.4.1997	19980451 26.4.1998 Pub Date. 12/2006	23685 9.5.2007	25.4.2018	<i>Activated Protein C. Formulations</i> The present invention relates to pharmaceutical formulations of activated protein C which comprises sucrose, sodium chloride and sodium citrate buffer at a PH between about 5.5 and 6.5. The activated protein C formulations of the present invention are more stable than formulations of activated protein C and demonstrate fewer degradation products over time.	<i>Patent Type: Product (Formulation)</i> This patent claims a stable lyophilized formulations of activated human protein C (also known as autoprothrombin IIA and blood coagulation factor XIV) and a bulking agent for treating vascular disorders. It is not clear whether this patent has any relevance to Eli Lilly's product Xigris, a recombinant form of protein C. This patent does not appear to relate to a


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
							marketed product as listed on the US FDA Orange Book.
4	American Home Products Corporation	US 08/373667 17.1.1995	19960047 17.1.1996 Pub Date. 1/2007	23687 13.5.2007	16.1.2016	<p><i>Controlled Release of Steroids from Sugar Coatings</i></p> <p>A sugar coating composition for application to a compressed medicinal tablet comprising a sugar, a dose of a hormonal steroid and a steroid release rate controlling amount of microcrystalline cellulose</p>	<p><i>Patent Type: Product (Composition)</i></p> <p>This patent claims a compressed, sugar-coated, pharmaceutical tablet containing two or more pharmacologically-active agents. The compressed tablet may contain excipients to provide rapid or slow release of the agents. The sugar coat contains a therapeutic amount of a hormonal steroid and a hormonal steroid release-controlling amount of microcrystalline cellulose.</p> <p>A preferred embodiment of the invention and as claimed is a compressed tablet in which the tablet core contains a unit dose of an estrogenic compound or a mixture thereof. Most desirably, the conjugated estrogens found in the tablet core comprises the naturally occurring conjugated estrogen product known as Premarin (used to treat vaginal dryness, itching and hot flashes).</p> <p>This patent relates to the marketed product Prempro (generic name estrogens conjugated medproxyprogesterone acetate) used to manage symptoms of menopause.</p>


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
5	Smithkline Beecham Plc	GB 9726568.0 16.12.1997	19981550 15.12.1998 Pub Date. 12/2006	23694 15.5.2007	15.12.2018	<p><i>Novel Pharmaceutical</i></p> <p>A hydrate of 5- {4-(N-methyl-N-(2-pyridyl) armino) ethoxy } benzyl} thiazolidine-2,4- dione, maleic acid, characterised in that it:</p> <p>(i) comprises water in the range of from 0.2 to 1.1% w/w; and (ii) provides an infra red spectrum containing peaks at 764 and 579 cm-1; and/or (iii) provides an X-ray powder diffraction (XRPD) pattern substantially a process for the preparation of such a compound, a pharmaceutical composition containing such a compound and the use of such a compound or composition in medicine .</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent covers a crystalline hydrate form of rosiglitazone maleate.</p> <p>Rosiglitazone maleate is marketed as Avandia for treating diabetes.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p> <p>(NB* The corresponding European patent application (EP 98966321.6 – Published as EP1045847) was refused but was granted in India as Patent No. 213203).</p>
6	F. Hoffman-La Roche AG	US 60/056718 22.8.1997	19980981 22.8.1998 2/2007	23729 28.6.2007	22.8.2017	<p><i>N-Alkanoylphenylalanine Derivatives</i></p> <p>Compounds of the formula:</p> 	<p><i>Patent Type: Product (Compound)</i></p> <p>The invention claims derivative compounds of N-alkanoylphenylalanine and their pharmaceutically acceptable salts and esters. These compounds are useful for treating chronic inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, bowel disease or asthma.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						As well as their salts and esters are disclosed wherein X,X', Z, and Y are as described in the specification and which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and/or damage are related to the binding of VCAM -1 to cells expressing VLA-4 .	This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.
7	F. Hoffman-La Roche AG	EP 97119031.9 31.10.1997 EP 98113851.4 24.7.1998	1998/1329 29.10.1998 Pub Date. 3/2007	23756 8.8.2007	28.10.2018	<p><i>D-Proline Derivatives</i></p> <p>The invention relates to D-prolines of the formula:</p>  <p style="text-align: right;">I-A</p> <p>or</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>The patent claims D-proline derivatives of the compounds R)-1-[(R)- 3-mercapto-2-methyl-propionyl]-pyrrolidine-2-carboxylic acid and (R)-1-[(S)-3-mercapto-2-methyl-propionyl]-pyrrolidine-2-carboxylic acid as disclosed in international applications WO 97/10225. The D-proline derivatives can be used to treat or prevent central and systemic amyloidosis.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						 <p style="text-align: center;">I-B</p> <p>wherein R is SH, benzyl or phenyl, optionally substituted by hydroxy or lower alkoxy or the group</p>  <p style="text-align: center;">;</p> <p>R' is hydrogen or halogen; X is - (CH₂)_n-; -CH(R₂)(CH₂)_n-; -CH₂O(CH₂)_n-; -CH₂NH-; benzyl, -C(R₂)=CH-; -CH₂CH(OH)-; or thiazol-2,5-diyl; Y is -S-S-; -(CH₂)_n-; -O-; -NH-; -N(R₂)-; -CH=CH-; -NHC(O)NH-; -N(R₂)C(O)N(R₂)-; -N(CH₂C₆H₅(OCH₃)₂)-; -N(CH₂C₆H₅)-; -N(CH₂C₆H₅)C(O)N(CH₂C₆H₅)-; -N(alkoxyalkyl)-; -N(cycloalkyl)-</p>	

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						<p>methyl)-; 2,6-pyridyl; 2,5-furanyl; 2,5-thienyl; 1,2-cyclohexyl; 1,3-cyclohexyl; 1,4-cyclohexyl; 1,2-naphthyl; 1,4-naphthyl; 1,5-naphthyl; 1,6-naphthyl; biphenylen; or 1,2-phenylen,1,3-phenylen and 1,4-phenylen, wherein the phenylen groups are optionally substituted by 1 - 4 substituents, selected from halogen, lower alkyl, lower alkoxy, hydroxy, carboxy, -COO-lower alkyl, nitrilo, 5-tetrazol, (2-carboxylic acid-pyrrolidin-1-yl)-2-oxo-ethoxy, N-hydroxycarbamimidoyl, 5-oxo-[1,2,4] oxadiazolyl, 2-oxo-[1,2,3,5]oxathiadiazolyl, 5-thioxo-[1,2,4]oxadiazolyl and 5-tert-butylsulfanyl-[1,2,4]oxadiazolyl; X' is -(CH₂)_n-; -(CH₂)_nCH(R₂)-; -(CH₂)_nOCH₂-; -NHCH₂-; benzyl, -CH=C(R₂)-; -CH(OH)CH₂; or thiazol-2,5-diyl; R₂ is lower alkyl, lower alkoxy or benzyl and n is 0-3, and to pharmaceutically acceptable salts and mono- and diesters thereof. The D-prolines of formula I-A and I-B can be used in the treatment or prevention of all forms of central and systemic amyloidosis.</p>	

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
8	Boehringer Ingelheim Pharma KG	DE 19843489.8 22.9.1998	1999/1180 22.9.1999 Pub Date. 3/2007	23757 8.8.2007	21.9.2019	<p><i>Benzoylguanidine derivatives with advantageous properties, processes for preparing them and their use in the production of pharmaceutical compositions</i></p> <p>The present invention relates to novel benzoylguanidine derivatives of general formula I</p>  <p>(I)</p> <p>preparing them and their use in the preparation of pharmaceutical compositions</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>The patent claims benzoylguanidine derivative compounds that have a higher efficacy of the oral bioavailability over compounds in the prior art.</p> <p>The benzoylguanidine derivative compounds are effective against arrhythmias, which occur for example during hypoxia.</p> <p>They are also applicable to diseases that are associated with ischemia (Examples: cardiac, cerbrale, gastrointestinal - as mensenteriale Throbse / embolism - pulmonary, renal ischemia, ischemia of the liver, skeletal muscle ischemia). Relevant diseases include coronary heart disease, myocardial infarction, angina pectoris, stable angina pectoris, ventricular arrhythmias, subventricular arrhythmias, heart failure - also in support of bypass operations, in support of open-heart operations, in support of operations, the interruption of blood supply of the heart and make it necessary for the support of heart transplant platation - embolism in the pulmonary circulation, acute or chronicKidney failure, chronic renal failure, cerebral infarction, reperfusion damage in the reperfusion of brain areas on the resolution of vascular occlusions, and</p>


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
							acute and chronic vascular disorders of the brain. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.
9	Pfizer Products Inc	US 60/089886 19.6.1998	1999/0725 16.6.1999 Pub Date. 3/2007	23758 8.8.2007	15.6.2019	<p><i>Pyrrolo [2,3-D] Pyrimidine Compounds</i></p> <p>A compound of formula (I)</p>  <p style="text-align: right;">(I)</p> <p>wherein R1, R2 and R3 are as defined in the formula which are inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent claims pyrrolo [2,3-d] pyrimidine compounds which are inhibitors of tyrosine kinases. The claims also cover a pharmaceutical composition for (a) treating or preventing a disorder or condition selected from organ transplant rejection, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukemia and other autoimmune diseases or (b) the inhibition of protein tyrosine kinases or Janus Kinase 3 (JAK3) in a mammal, including a human, comprising an amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional agents which modulate a mammalian immune system or with</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.	antiinflammatory agents, effective in such disorders or conditions and a pharmaceutically acceptable carrier. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.
10	Schering Corporation	US 60/172836 20.12.1999	2000/1571 20.12.2000 Pub Date. 3/2007	23759 8.8.2007	19.12.2020	<i>Stable extended release oral dosage composition</i> A film-coated extended release solid oral dosage composition containing a nasal decongestant, pseudoephedrine or salt thereof, e.g., pseudoephedrine sulfate in a core effective to provide a geometric maximum plasma concentration of pseudoephedrine of about 345 ng/mL to about 365 ng/mL at a time of about 7.60 hrs to about 8.40 hrs and having two or three film-coatings on the core, the second one containing an amount of the non-sedating antihistamine, desloratadine, effective to provide a geometric maximum plasma concentration of desloratadine of about 2.15 ng/mL to about 2.45 ng/mL at a time of about 4.0 hours to about 4.5 hours, and use of the composition for treating	<i>Patent Type: Product (Composition/Formulation)</i> This patent claims a extended release solid oral dosage composition comprising pseudoephedrine or pharmaceutically acceptable salt thereof, and (b) a film coating uniformly covering the core and comprising an effective amount of desloratadine useful for the relief of nasal and non-nasal symptoms of seasonal allergic rhinitis, including nasal congestion. This patent relates to the product Clarinex D 12 and 24 hour (generic name desloratadine).


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						patients showing the signs and symptoms associated with allergic and/or inflammatory conditions of the skin and airway passages are disclosed.	
11	Sanofi	FR 9800514 19.1.1998	1999/0055 16.1.1999 Pub Date. 3/2007	23760 8.8.2007	15.1.2009	<p><i>Novel Pentasaccharides Processes for Their Preparation and Pharmaceutical Compositions Containing Them</i></p> <p>The invention relates to a pentasaccharide in an acid form and its pharmaceutically acceptable salts, the anionic form of which is described by formula (I):</p>  <p>in which R1 is (C1-C3) alkyl; R is hydrogen, an -SO3<-> group, (C1-C3) alkyl or (C2-C3) acyl; T is hydrogen or an ethyl group; and n is 1 or 2.</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent claims new pentasaccharides, their salts (also known as idraparinix sodium) and methods of preparation for treating venous thromboembolism.</p> <p>Sanofi conducted phase II clinical trials on these compounds, but it appears to have not been approved for marketing.</p> <p>(These compounds have a similar chemical structure to fondaparinux (marketed as Arixtra) by GlaxoSmithKline.)</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
12	Sanofi	FR 97/07795 23.6.1997	1998/0720 21.6.1998 Pub Date. 3/2007	23762 8.8.2007	20.6.2018	<p><i>Solid pharmaceutical composition containing benzofuran</i></p> <p>The present invention relates to a solid pharmaceutical composition for oral administration, characterised in that it comprises a benzofurane derivative with antiarrhythmic activity or one of its pharmaceutically acceptable salts thereof, as an active principle, and a pharmaceutically acceptable non-ionic hydrophilic surfactant, optionally in combination with one or more pharmaceutical excipients.</p>	<p><i>Patent Type: Product (Composition)</i></p> <p>This patent claims a pharmaceutical composition for oral administration of the benzofuran derivative, dronedarone and its pharmaceutical salts, wherein the pharmaceutically acceptable salt is hydrochloride.</p> <p>This patent relates to the marketed product Multaq (dronedarone hydrochloride) an antiarrhythmic drug to treat atrial fibrillation/flutter.</p>
13	Eli Lilly & Co.	US 08/308325 19.9.1994 US 08/427914 26.4.1995	1995/0763 17.9.1995 Pub Date. 3/2007	23763 8.8.2007	16.9.2015	<p><i>Novel pharmaceutical product</i></p> <p>The present invention is directed to a novel non-solvated crystalline form of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]-benzo[b]thiophene hydrochloride.</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent claims a non-solvated crystalline form and a crystalline form of the compound 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene hydrochloride and process for their making.</p> <p>The compounds are useful for treating osteoporosis, serum lipid lowering, and breast cancer.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
14	U C B SA	EP 97870193.6 26.11.1997	1998/1476 25.11.1998 Pub Date. 2/2007	23776 8.8.2007	24.11.2018	<p><i>New pseudopolymorphic forms of 2-(2,4)-bis(4-fluorophenyl) methyl-1-piperazinyl ethoxy acetic acid dihydrochloride</i></p> <p>The present invention relates to new pseudopolymorphic forms of 2-2-4-bis(4-fluorophenyl) methyl-1-piperazinyl ethoxy acetic acid dihydrochloride, namely, anhydrous 2-2-4-bis (4-fluorophenyl) methyl-1-piperazinyl ethoxy acetic acid dihydrochloride and 2-2-4-bis (4-fluorophenyl) methyl-1-piperazinyl ethoxy acetic acid dihydrochloride monohydrate. It also relates to processes for the preparation of these pseudopolymorphic forms and to pharmaceutical compositions containing them.</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent claims new pseudopolymorphic forms of efletirizine, including the process for making the compound. The claims also cover a pharmaceutical composition comprising anhydrous form of efletirizine.</p> <p>Efletirizine is useful as an antiallergic, antihistaminic, bronchodilator and antispasmodic agent.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>
15	H Lundbeck A/S	DK 126/97 7.11.1997	1998/1362 3.11.1998 Pub Date. 2/2007	23791 13.8.2007	2.11.2018	<p><i>1-(4-(1-4-Fluorophenyl-1H-indole-3-yl-1-butyl spiro (isobenzofuran 1-(3H), 4-Piperidine) hydrohalogenides</i></p> <p>The present invention relates to a</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>The invention relates to pharmaceutical compositions containing the hydrohalogenide salts of 1' -[4- [1 -(4-</p>


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						<p>hydrohalogenide of 1'- [4-[1- (4-fluorophenyl) -1H-indole- 3-yl]-1-butyl]- spiro[isobenzofuran-1(3H),4'-piperidine], pharmaceutical compositions containing the acid addition salts and the use thereof for the treatment of psychic and neurological disorders.</p> 	<p>fluorophenyl)- 1H-indole-3-yl]- 1 -butyl] spiro[isobenzofuran-1(3H),4'-piperidine] and their hydrates and/or solvates pharmaceutical for the treatment of anxiety, psychoses, epilepsy, convulsion, movement disorders, motor disturbances, amnesia, cerebrovascular diseases, senile dementia of Alzheimer type and Parkinson's disease.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>
16	Smithkline Beecham Corporation	US 60/038196 14.2.1997	1998/0154 11.2.1998 Pub Date. 3/2007	23780 12.8.2007	10.2.2018	<p><i>Process for preparing eprosartan</i></p> <p>The present invention provides a process for the preparation of eprosartan which is (E) -a [[2-butyl-1-(4-carboxyphenyl) methyl] - 5-imidazol-2-thiophene propanoic acid, compound of formula -2-yl]methylene -(1): or a pharmaceutically acceptable salt thereof</p>	<p><i>Patent Type: Process</i></p> <p>This patent covers an improved process for preparing the compound eprosartan mesylate.</p> <p>Eprosartan is marketed in the US by Abbott Laboratories under the brand name Teveten and is used to treat high blood pressure.</p> <p>(Eprosartan may be marketed under a different brand name in Egypt and be available in generic form given the base</p>


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
							compounds including eprosartan were discovered in 1991).
17	Novo Nordisk	DK 95/0523 5.5.1995	1996/0385 5.5.1996 Pub Date. 3/2007	23781 13.8.2007	4.5.2016	<p><i>Pharmaceutical composition containing tiagabine hydrochloride and the process for its preparation</i></p> <p>The subject matter of the present invention is a pharmaceutical composition intended for the preparation of dosage forms and in particular solid dosage forms containing an efficacious quantity of tiagabine hydrochloride or of one of its pharmaceutically acceptable salts as active ingredient and characterised in that it contains at least one pharmaceutically acceptable antioxidant agent, in a sufficient quantity to stabilise the active ingredient.</p>	<p><i>Patent Type: Product (Composition)</i></p> <p>This patent claims a pharmaceutical composition comprising the compound tiagabine or a pharmaceutical salt thereof, one or more pharmaceutically acceptable antioxidants and optionally a pharmaceutically acceptable carrier.</p> <p>This patent relates the product marketed under the brand name Gabitril (generic name tiagabine) by Cephalon and is used to treat partial seizures.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
18	Almirall Prodesfarma SA	ES 199802011 25. 9.1998 ES 199900619 26.3.1999	1999/1189 25.9.1999 Pub Date. 4/2007	23802 22.8.2007	24.9.2019	<p>2-Phenylpyran-4-one derivatives</p> <p>2-Phenylpyran-4-one derivatives of formula (I):</p>  <p>(I)</p> <p>wherein R1 represents an alkyl or -NR4 R5 group, wherein R4 and R5 each independently represents a hydrogen atom or an alkyl group; R2 represents an alkyl, C3-C7 cycloalkyl, pyridyl, thienyl, naphthyl, tetrahydronaphthyl or indanyl group, or a phenyl group which may be unsubstituted or substituted by one or more halogen atoms or alkyl, trifluoromethyl, hydroxy, alkoxy, methylthio, amino, mono- or dialkylamino, hydroxyalkyl or hydroxycarbonyl groups; R3 represents a methyl, hydroxymethyl, alkoxymethyl, C3-C7 cycloalkoxymethyl,</p>	<p>Patent Type: Product (Compound)</p> <p>This patent claims 2-Phenylpyran-4-one derivatives and processes for their preparation and pharmaceutical compositions.</p> <p>Compounds are useful in the treatment of COX-2 mediated diseases, such as inflammation, pain, fever and asthma with fewer side effects.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						benzyloxymethyl, hydroxycarbonyl, nitrile, trifluoromethyl or difluoromethyl group or a CH ₂ -R ₆ group wherein R ₆ represents an alkyl group; and X represents a single bond, an oxygen atom, a sulfur atom or a methylene group; or pharmaceutically acceptable salts thereof, processes for their production and synthetic intermediates used in said processes, pharmaceutical compositions containing them and their use in medical treatment.	
19	Akzo Nobel Sanofi		1998/01526 9.12.1998 Pub Date. 5/2007	23813 12.9.2007	8.12.2018	<p><i>Carbohydrate derivatives</i></p> <p>The invention relates to carbohydrate a derivative having formula (I):</p> <p>[See Abstract for compound Structure]</p> <p>wherein R₁ is (1-4C) alkoxy, R₂, R₃ and R₄ are independently (1-4c) alkoxy or OSO₃, the total number of sulfate groups is 4, 5, or 6, and the twisted lines represent bounds either above or below the plane of the six-membered ring to which they are attached or a pharmaceutically acceptable salt thereof. The</p>	Information not available.

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						compounds of the invention have antithrombotic activity and may be used for treating or preventing thrombosis and for inhibiting smooth, cell proliferation.	
20	Yamanouchi Europe BV	EP 96201829.7 3.7.1996 US 08/770421 20.12.1996	1997/0623 2.7.1997 Pub Date. 5/2007	23814 12.9.2007	1.7.2017	<p><i>Granulate for the preparation of fast disintegrating and fast dissolving compositions containing a high amount of drug</i></p> <p>A granulate, containing an active ingredient, having a solubility in water of 1:>10, in admixture with </=15 wt.% of a water dispersible cellulose, is provided for the preparation of fast-disintegrating and fast-dissolving compositions.</p>	<p><i>Patent Type: Method/Type of Formulation</i></p> <p>This patent covers granulate, that is fast disintegrating and fast dissolving and can be used with an active ingredient.</p> <p>The patent claims do not claim any particular active ingredient.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>
21	Eli Lilly & Co	US 60/026486 23.9.1996	1997/0985 23.9.1997 Pub Date. 4/2007	23815 19.9.2007	22.9.2017	<p><i>Olanzapine dihydrated</i></p> <p>The present invention provides the novel dihydrate D 2-methyl-thieno-benzodiazepine and a formulation therefore.</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This invention claims the crystalline dihydrate D of 2-methyl-4-(4-methyl-1-piperaziny)-10H-thieno[2,3-b][1,5]benzodiazepine (olanzapine) and formulations using the crystalline form</p>



	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
							useful for preparing an aqueous olanzapine formulation. This patent relates to the marketed product Zyprexa used for treating symptoms of schizophrenia.
22	Pfizer Products Inc	US 60/070245 31.12.1997	1998/1612 28.12.1998 Pub Date. 4/2007	23816 19.9.2007	27.12.2018	<p>Aryl fused azapolycyclic compounds</p> <p>Compounds of formula (I)</p>  <p>and their pharmaceutically acceptable salts, wherein R1, R2, R3 and n are defined as in the specification, intermediates in the synthesis of such compounds, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of neurological and psychological disorders are claimed.</p>	<p><i>Patent Type: Product (Compounds)</i></p> <p>The patent claims aryl fused azapolycyclic compounds, including 5,8,14-triazatetracyclo[10.3.1.0<2,11>.0<4,9>]hexa deca-2(11),3,5,7,9-pentaene (generic name varenicline) which bind to neuronal nicotinic acetylcholine specific receptor sites and are useful in modulating cholinergic function.</p> <p>This patent covers the base compound varenicline and relates to the marketed product Chantix, used to treat smoking addiction.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
23	F.Hoffmann-La Roche AG	EP 99103504.9 24.2.1999 EP 99123689.4 29.11.1999	20000206 22.2.2000 Pub Date. 4/2007	23817 19.9.2007	21.2.2020	<p>4-Phenyl-pyridine derivatives</p> <p>The present invention relates to compounds of the general formula:</p>  <p>wherein R is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl ; R1 is hydrogen or halogen ; or R and R1 may together- CH:CH-CFI:CH, R2 and R2 are independently from each other hydrogen, halogen trifluoromethyl, lower alkoxy or cyani; or R2 and R2 may be together- CH:CH-CH:CH-, optionally substituted by one or two substituents selected from lower alkyl or lower alkoxy ; R3 is hydrogen, lower alkyl or form a cycloalkyl group; R4 is hydrogen, - N (R5)2, - N(R5), (CH2) n OH, N(R5) S (O)2 - lower alkyl, - N(R5)S(O)2- phenyl,-</p>	<p><i>Patent Type: Product (Compounds)</i></p> <p>This patent claims various 4-phenyl-pyridine compounds which are useful for treating headache, anxiety, multiple sclerosis, attenuation of morphine withdrawal, cardiovascular changes, oedema, such as oedema caused by thermal injury, chronic inflammatory diseases such as rheumatoid arthritis, asthma/bronchial hyperreactivity and other respiratory diseases including allergic rhinitis, inflammatory diseases of the gut including ulcerative colitis and Crohn's disease, ocular injury and ocular inflammatory diseases.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						N=CH-N(R5)2, - N(R5)2, -N(R5)2; C(O)R5	
24	Pfizer Products Inc	US 60/104024 13.10.1998	1999/1275 12.10.1999 Pub Date. 4/2007	23818 19.9.2007	11.10.2019	<p><i>Sertraline oral concentrate</i></p> <p>The present invention provides an essentially non-aqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The present invention also provides a use of this concentrate composition to prepare an aqueous solution of sertraline. In addition, the present invention provides a method of using this concentrate composition to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine methanesulfonate.</p>	<p><i>Patent Type: Product (Composition)</i></p> <p>The patent covers a pharmaceutical composition comprising an essentially nonaqueous, liquid concentrate for oral administration comprising an amount of sertraline or a pharmaceutically acceptable salt thereof (namely hydrochloride or mesylate salt) and one or more essentially nonaqueous pharmaceutically acceptable excipients; wherein at least one of the excipients is liquid.</p> <p>This patent relates to the marketed product Zoloft (generic name sertraline), used to treat depression, obsessive-compulsive disorders, panic attacks, post traumatic stress disorders and social anxiety disorders.</p>
25	Boehringer Ingelheim Pharma KG	DE 19902229.1 21.1.1999	2000/0058 18.1.2000	23819 19.9.2007	17.1.2020	<p><i>Method for preparing of l-phenylephrine-hydrochloride</i></p>	<p><i>Patent Type: Process/Method</i></p> <p>The patent claims an improved method for</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
			4/2007			The invention relates to an improved method for the industrial-scale production of L-phenylephrine hydrochloride 3 by asymmetric hydrogenation as key step and a special series of subsequent steps. According to the invention [Rh(COD)Cl] ₂ is used as catalyst and a chiral, bidentate phosphine ligand such as (2R, 4R)-4-(dicyclohexylphosphino)-2-(diphenylphosphino-methyl)-N-methyl-aminocarbonyl-pyrrolidine is used as catalyst system.	manufacturing L-phenylephrine hydrochloride, useful as a sympathomimetic in the treatment of hypotension and as a vasoconstrictor in the eye and nose medicine.
26	Boehringer Ingelheim Pharma KG	DE 198479696.7 17.10.1998	19991295 17.10.1999 Pub Date. 5/2007	23820 19.9.2007	16.10.2019	<i>Liquid formulation with formoterol suitable for storage</i> The present invention relates to a formoterol active substance concentrate suitable for storage, in the form of a solution or suspension for use in inhalers for inhalation or nasal therapy.	<i>Patent Type: Product (Formulation)</i> The patent covers a storage-stable formulation of formoterol in the form of a solution or suspension for use in inhalers. Formoterol is used as a beta-stimulator in inhalation therapy of lung diseases, in particular treatment of bronchial asthma. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
							According to the US FDA Orange Book there are various inhalation products comprising formoterol, including generic versions.
27	Astra Aktiebolag	SE 9600071.6 8.1.1996	19970018 7.1.1997 Pub Date. 5/2007	23821 19.9.2007	6.1.2017	<p><i>Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate</i></p> <p>An oral pharmaceutical dosage form comprising an acid susceptible proton pump inhibitor and one or more antacid agents or an alginate in a fixed formulation, wherein the proton pump inhibitor is protected by an enteric coating layer and an optional separating layer in between the proton pump inhibitor and the enteric coating. The fixed formulation is in the form of multilayered tablets, sachets or multiple unit tableted dosage forms. The multiple unit dosage form is most preferred. The new fixed formulation is especially useful in the treatment of disorders associated with dyspepsia such as heartburn.</p>	<p><i>Patent Type: Product (Dosage Form)</i></p> <p>The patent claims an oral pharmaceutical dosage form comprising an acid susceptible proton pump inhibitor and one or more antacid agents or an alginate in a fixed formulation for use in the prevention and treatment of dyspeptic symptoms i.e. upper abdominal pain/discomfort and heartburn. In particular the patent claims the dosage form and susceptible proton pump inhibitor as being omeprazole, one of its single enantiomers and an alkaline salt (e.g. (s) omeprazole and a magnesium salt or lansoprazole).</p> <p>The base patents for omeprazole and lansoprazole have both expired.</p> <p>Therefore, the scope of protection of this patent is only limited to the particular dosage form.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
28	Pfizer Research and Development Company NV/SA	GB 9417310.1 27.8.1994	19950711 26.8.1995 Pub Date. 5/2007	23822 19.9.2007	25.8.2015	<p><i>Salts of an anti-migraine indole derivatives</i></p> <p>The invention relates to an alpha - polymorphic form of a compound of formula (I), to processes for the preparation thereof, to an intermediate beta -polymorphic form, and to pharmaceutical compositions and therapeutic uses thereof.</p> 	<p><i>Patent Type: Product (Compound and Composition)</i></p> <p>This patent covers a polymorphic form of the compound eletriptan and pharmaceutical compositions using the polymorphic form.</p> <p>This patent relates to the marketed product Relpax, used to treat symptoms of migraine headache</p>
29	Pfizer Products Inc	US 60/109399 20.11.1998	19991476 17.11.1999 Pub Date. 5/2007	23823 19.9.2007	16.11.2019	<p>13-Membered azalides and their use as antibiotic agents</p> <p>The invention relates to a method of preparing compounds of formula (1):</p> 	<p><i>Patent Type: Product (Compound)</i></p> <p>The patent claims 13-membered azalides (macrolide compounds related to antibiotics like erythromycin and azithromycin) compounds useful as antibacterial and antiprotozoa agents and methods for making the said compounds.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						and to pharmaceutically acceptable salts thereof. The compounds of formula (1) are antibacterial agents that may be used to treat various bacterial and protozoa infections. The invention also relates to pharmaceutical compositions containing the compounds of formula (1) and to methods of treating bacterial protozoa infections by administering the compounds of formula (1). The invention also relates to methods of preparing the compounds of formula (1) and to intermediates useful in such preparation.	
30	Pfizer Research and Development Company NV/SA	GB 9518953.6 15.9.1995	19960822 12.9.1996 Pub Date. 4/2007	23826 25.9.2007	11.9.2016	<i>Pharmaceutical formulations</i> There is provided a pharmaceutical dosage form adapted for administration to the gastrointestinal tract of a patient, comprising darifenacin, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier; characterized in that the dosage form is adapted to deliver at least 10 % by weight of the darifenacin, or the pharmaceutically acceptable salt	<i>Patent Type: Product (Dosage Form)</i> This patent claims a pharmaceutical dosage form comprising the compound darifenacin (an antimuscarinic). This patent relates to the marketed product Enblex, used to treat an overactive bladder.

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						thereof, to the lower gastrointestinal tract of the patient. The formulation minimizes unwanted side-effects and increases the bioavailability of darifenacin.	
31	Glaxo Group Limited	GB 9709945.1 17.5.1997	19980526 14.5.1998 Pub Date. 3/2007	23836 2.10.2007	13.5.2018	<p><i>A novel salt</i></p> <p>There is described the hemisulfate salt of (1S, 4R)-<u>cis</u>-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol or a solvate thereof. Also described are preparative routes and starting compounds for making the hemisulfate salt. The hemisulfate salt is useful in medicine, particularly in the treatment of viral infections.</p>	<p><i>Patent Type: Product (Salt of a Compound and Formulation)</i></p> <p>This patent claims the hemisulfate salt of abacavir and its pharmaceutical formulation.</p> <p>This patent relates to the marketed product Ziagen for treating HIV/AIDS and Hepatitis B.</p>
32	Janssen Pharmaceutica NV	EP 01200611.0 21.2.2001 EP 01201264.7 5.4.2001	2002/0197 19.2.2002 Pub Date. 8/2007	23929 15.1.2008	18.2.2022	<p><i>Isoxazolines derivatives and their use as antidepressants</i></p> <p>The invention concerns substituted isoxazolines derivatives according to Formula (I):</p>  <p style="text-align: right;">(I)</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>The patent claims substituted isoxazolines derivatives and having anti-depressant activity and/or anxiolytic activity and/or body weight control activity, and their pharmaceutical compositions.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						<p>wherein X = CH₂, N-R₇, S or O, R₁, R₂ and R₃ are certain specific substituents, Pir is an optionally substituted piperidyl or piperazyl radical and R₃ represents an optionally substituted aromatic homocyclic or heterocyclic ring system including a partially or completely hydrogenated hydrocarbon chain of maximum 6 atoms long with which the ring system is attached to the Pir radical and which may contain one or more heteroatoms selected from the group of O, N and S; a process for their preparation, pharmaceutical compositions comprising them and their use as a medicine, in particular for the treatment of depression and/of anxiety and disorders of body weight. The compounds according to the invention have surprisingly been shown to have a serotonin (5-HT) reuptake inhibitor activity in combination with additional α₂-adrenoceptor antagonist activity and show a strong anti-depressant activity without being sedative.</p>	


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
33	Smithkline Beecham Plc	GB 9514842.5 20.7.1995	1996/0682 18.7.1996 Pub Date. 8/2007	23934 14.1.2008	17.7.2006	<i>Novel Formulation</i> A controlled release or delayed release formulation contains a selective serotonin reuptake inhibitor (SSRI) such as paroxetine.	<i>Patent Type: Product (Formulation)</i> This patent claims a controlled release formulation with enteric coated tablets, wax or copolymer tablets or time-released matrices comprising the compound paroxetine. The patent relates to the marketed product Paxil, used to treat depression, panic disorder and social anxiety disorder.
34	Smithkline Beecham Corporation	US 60/038195 14.2.1997	1998/0155 11.2.1998 Pub Date. 8/2007	23935 14.1.2008	10.2.2018	<i>Process for preparing eprosartan</i> This invention relates to a process for preparing eprosartan.	<i>Patent Type: Process</i> This patent covers a process for preparing the compound eprosartan. Eprosartan is marketed in the US by Abbott Laboratories under the brand name Teveten and is used to treat high blood pressure. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book. This product may be marketed under a different brand name in Egypt and be available in generic form given the base compounds including eprosartan were discovered in 1991.

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
35	Bristol Myers Squibb Co.	US 60/071968 20.1.1998	1999/0056 17.1.1999 Pub Date. 8/2007	23936 14.1.2008	16.1.2019	<p><i>Bisulfate Salt of HIV Protease Inhibitor</i></p> <p>The present invention provides the crystalline bisulfate salt of formula (II):</p>  <p>which is found to have unexpectedly high solubility/dissolution rate and oral bioavailability relative to the free base form of this azapeptide HIV protease inhibitor compound.</p>	<p><i>Patent Type: Compound (Salt)</i></p> <p>This patent claims the bisulfate salt of atazanavir.</p> <p>This patent relates to the marketed product Reyataz for treating HIV/AIDS.</p>
36	Smithkline Beecham Plc	GB 9909471.6 23.4.1999 GB 9912195.6 25.5.1999	2000/0511 22.4.2000 Pub Date. 8/2007	23937 14.1.2008	21.4.2020	<p><i>Novel Pharmaceutical</i></p> <p>A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt (the "Polymorph") characterised in that it provides: (i) an infra red spectrum containing peaks at 1752, 1546, 1154, 621, and 602 cm^{-1}; and/or</p>	<p><i>Patent type: Product (Compound)</i></p> <p>The patent covers a polymorphic form of rosiglitazone maleate .</p> <p>This patent is listed on the US FDA Orange book as being related to the marketed product Avandaryl (a combination of the compounds glimepiride and rosiglitazone maleate) to</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						<p>(ii) a Raman spectrum containing peaks at 1751, 1243 and 602 cm⁻¹; and/or (iii) a solid-state nuclear magnetic resonance spectrum containing peaks at 111.9, 114.8, 119.6, 129.2, 134.0, 138.0, 144.7, 153.2, 157.1, 170.7, 172.0 and 175.0 ppm; and/or (iv) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings of 6.46, 5.39, 4.83, 4.68, 3.71, 3.63, 3.58, and 3.48 Angstroms; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine. A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt (the "Polymorph") characterised in that it provides: (i) an infra red spectrum containing peaks at 1752, 1546, 1154, 621, and 602 cm⁻¹; and/or (ii) a Raman spectrum containing peaks at 1751, 1243 and 602 cm⁻¹; and/or (iii) a solid-state nuclear magnetic resonance spectrum containing peaks at 111.9, 114.8, 119.6, 129.2, 134.0, 138.0, 144.7, 153.2, 157.1, 170.7, 172.0 and 175.0</p>	<p>help control blood sugar levels within patients who have type 2 diabetes.</p>


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						ppm; and/or (iv) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings of 6.46, 5.39, 4.83, 4.68, 3.71, 3.63, 3.58, and 3.48 Angstroms; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine.	
C	Bristol-Myers Squibb Co.	US 09/547948 12.4.2000	2000/0818 26.6.2000 Pub Date. 9/2007	23943 22.1.2008	25.6.2020	<p><i>Flash-melt oral dosage form</i></p> <p>There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination consisting of a superdisintegrant, a dispersing agent, a distributing agent, and a binder and may also include other conventional ingredients such as sweetening and flavoring agents. The subject granules are advantageous in that they are stable and can be prepared without the aid of solvents and without the need for special environments or handling. Dosage forms, especially tablets, prepared therefrom on conventional equipment disintegrate in the mouth in under</p>	<p><i>Patent Type: Product (Dosage Form)</i></p> <p>The patent covers a flash-melt pharmaceutical dosage form comprising a medicament (selected from the group consisting of aripiprazole, aripiprazole, chlorpheniramine maleate, pseudoephedrine, diphenhydramine HCl, phenylpropanolamine, cimetidine, loperamide, meclizine, entecavir, cefprozil, pravastatin, captopril, fosinopril, irbesartan, omapatrilat, gatifloxacin and desquinalone) and a combination of four excipients consisting of a superdisintegrant, a dispersing agent, a distributing agent and a binder.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
38	Bristol-Myers Squibb Co.	US 09/118418 17.7.1998	1999/0800 3.7.1999 Pub Date. 9/2007	23944 22.1.2008	2.7.2019	<p>about twenty five seconds.</p> <p><i>Enteric coated pharmaceutical tablet and method of manufacturing</i></p> <p>A high drug load enteric coated pharmaceutical composition is provided which includes a core in the form of a tablet and which is comprised of a medicament which is sensitive to a low pH environment of less than 3, such as ddl, and having an enteric coating formed of methacrylic acid copolymer and a plasticizer. The tablets may be of varying sized and may be orally ingested individually or a plurality of tablets sufficient to attain a desired dosage may be encapsulated in a dissolvable capsule. The tablets have excellent resistance to disintegration at pH less than 3 but have excellent drug release properties at pH greater than 4.5. A novel method of making said pharmaceutical composition is also disclosed.</p>	<p><i>Patent Type: Product (Pharmaceutical Composition)</i></p> <p>This patent claims an enteric coated pharmaceutical composition comprising a core in the form of a tablet and having an enteric coating surrounding said core, said core comprising an acid labile medicament, a binder or filler, a disintegrant, and a lubricant, said enteric coating comprising a methacrylic acid copolymer, and a plasticizer, and imparting protection to said core so that said core is afforded protection in a low pH environment of 3 or less while capable of releasing medicament at a pH of 4.5 or higher.</p> <p>Medicaments claimed for use with the pharmaceutical composition include, didanosine, pravastatin, erythromycin, digoxin and pancreatin, ddA (dideoxyadenosine) and ddC (zalcitabine (also known as dideoxycytidine)).</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
39	Smithkline Beecham Corporation	US 60/070718 7.1.1998 US 60/106908 26.10.1998	1999/0014 6.1.1999 Pub Date. 9/2007	23945 22.1.2008	5.1.2019	<p><i>Method for treating COPD</i></p> <p>A method for treating COPD comprising administering compounds of Formula (I)</p>  <p style="text-align: center;">(I)</p> <p>where X4 is a 1-substituted cyclohexyl group.</p>	<p><i>Patent Type: Method of Treatment/Use</i></p> <p>This patent claims a method for treating chronic obstructive pulmonary disease (COPD) using various compounds.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>
40	Smithkline Beecham Plc	GB 9909075.5 20.4.1999	2000/0501 19.4.2000 Pub Date. 9/2007	23946 22.1.2008	18.4.2020	<p><i>Novel Pharmaceutical</i></p> <p>5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, hydrochloride monohydrate characterised in that it:</p> <p>(i) provides an infra red spectrum containing peaks at 3358, 2764, 1245, 833 and 760 cm⁻¹; and/or</p> <p>(ii) provides an X-ray powder diffraction (XRPD) pattern containing peaks at 15.0, 17.7, 23.0, 30.0 and 31.4 DEG 2 theta ; a process for preparing such a</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent covers hydrochloride hydrate forms of the compound rosiglitazone, useful for treating and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine.	
41	Otsuka Pharmaceutical Co Ltd	JP 11/81363 25.3.1999 JP 11/279147 30.9.1999	2000/0310 11.3.2000 Pub Date. 9/2007	23951 29.1.2008	10.3.2020	<i>Cilostazol preparation</i> Provided is a cilostazol preparation which comprises incorporating a fine powder of cilostazol into a dispersing and/or solubilizing agent thereby to enhance the dispersibility and/or solubility. Further, provided is a process for improving absorbability of a slightly soluble drug such as cilostazol even at the lower portion of the digestive tract, wherein said drug is hard to be absorbed at the lower portion of the digestive tract when a conventional method is used. According to the present invention, cilostazol is absorbed enough even at the lower portion of the digestive tract to have an effect as thrombolytic drug, cerebral circulation improving drug or the like.	<i>Patent Type: Product (Pharmaceutical Preparation)</i> This patent claims a pharmaceutical preparation for dissolving the medicament cilostazol at the lower portion of the digestive tract, comprising incorporating a fine powder of cilostazol as an active ingredient into a dispersing and/or solubilizing agent. Cilostazol is used to to alleviate the symptom of intermittent claudication in individuals with peripheral vascular disease. Cilostazol marketed by Otsuka under the brand name Pletal, but is also available in generic form. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.
42	Merck & Co Inc	US 60/256799 20.12.2000	2001/1350 22.12.2001	23966 13.2.2008	21.12.2021	<i>Process for making substituted 8-arylquinolinium benzenesulfonate</i>	<i>Patent Type: Process/Method</i> This patent covers a process for making the

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
			Pub Date.			A substituted 8-aryl quinoline and its benzenesulfonic acid salt is synthesized.; The present invention is directed to a process to synthesize 6-[1-methyl-1-(methylsulfonyl)ethyl]-8-[3(E)-2-[3-methyl-1,2,4-oxadiazol-5-yl]-2-[4-(methylsulfonyl)phenyl]ethenyl]phenyl]quinoline and its benzenesulfonic acid salt.	benzenesulfonic acid salt of a substituted 8-arylquinolines, in particular the compound 6- [1-methyl-1- (methylsulfonyl) ethyl]-8- [3- [(E)-2- [3-methyl-1, 2,4-oxadiazol-5-yl]- 2- [4 (methylsulfonyl) phenyl] ethenyl] phenyl] quinolinium benzenesulfonate which is a phosphodiesterase-4 inhibitor. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.
43	Laboratoires Fournier SA	FR 97/00479 17.1.1997	1998/2052 17.1.1998 Pub Date. 10/2007	23978 26.2.2007	16.1.2018	<i>Pharmaceutical composition of fenofibrates presenting a high biodisponibility and process for preparation thereof.</i> The invention concerns a fenofibrate composition with instant release comprising: (a) an inert water-soluble support coated with at least a film containing an active fenofibrate principle in micronised form with a size less than 20 µm, a hydrophilic polymer and optionally a surfactant; said hydrophilic polymer representing at least 20 wt.% of the weight of element (a), and (b) optionally one or several external phase(s) or film(s). The invention also concerns its method of preparation.	<i>Patent Type: Product (Pharmaceutical Composition)</i> The patent covers composition comprising: (a) a dispersible inert support coated with at least one layer containing an active ingredient fenofibrate micronized form with a size less than 10 µm, a hydrophilic polymer and optionally a surfactant, said hydrophilic polymer with at least 10% by weight of the weight of component a) and (b) optionally one or more phase (s) or layer (s) External (s) 2. The composition of claim 1, wherein a surfactant is present with the active ingredient and the hydrophilic polymer. This patent relates to the product Tricor – generic name fenofibrate (marketed by Abbott Laboratories) used with dieting to


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
							lower triglycerides, total cholesterol, and LDL (bad) cholesterol and increase HDL (good) cholesterol as well as excess body weight, drinking alcohol, diseases such as diabetes and certain thyroid problems.
44	F.Hoffmann-La Roche AG	EP 99108199 27.4.1999	2000/0523 24.4.2000 Pub Date. 9/2007	23979 27.2.2008	23.4.2020	<p><i>Renin Inhibitors</i></p> <p>The present invention relates to compound of formula (I):</p>  <p style="text-align: right;">(I)</p> <p>wherein R1, R2 and R3 are as defined in the description and claims and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment of diseases which are associated restenosis, glaucoma, cardiac infarct, high blood pressure and end organ damage, e.g. cardiac insufficiency and kidney</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>The patent claims various rennin inhibitor compounds, their pharmaceutical compositions and process for preparing the compounds.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						insufficiency.	
45	Astra Aktiebolag	SE 9900274.3 28.1.1999	2000/0088 25.1.2000 Pub Date. 9/2007	23980 27.2.2008	24.1.2020	<p><i>Potassium salt of (s)-omeprazole</i></p> <p>The present invention relates to a novel form of 5- methoxy- 2- [[(4- methoxy- 3,5- dimethyl- 2- pyridinyl) methyl] sulfinyl] -1H- benzimidazole, known under the generic name omeprazole. More specifically, it relates to a novel crystalline form of the potassium salt of the (S)- enantiomer of 5- methoxy- 2- [[(4- methoxy- 3,5- dimethyl- 2- pyridinyl) methyl] sulfinyl] -1H- benzimidazole. The present invention also relates to processes for preparing such a form of the potassium salt of (S)- omeprazole and pharmaceutical compositions containing it.</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent claims a potassium salt of (S)- omeprazole in a hydrate and crystalline form, and the process for their preparation.</p> <p>Omeprazole is useful as an anti-ulcer agent and in the treatment of gastric-acid related diseases. Omeprazole is available marketed in generic form.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>
46	Boehringer Ingelheim KG	DE 19653969.2 20.12.1996	1997/1353 18.12.1997 Pub Date. 9/2007	23981 27.2.2008	17.12.2017	<p><i>New aqueous pharmaceutical preparation for the production of a propellant-free aerosol</i></p> <p>The invention relates to pharmaceutical preparation in the</p>	<p><i>Patent Type: Product (Pharmaceutical Preparation)</i></p> <p>This patent claims a pharmaceutical preparation in the form of a solution for</p>


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						form of aqueous solutions for the production of propellant gas-free aerosols.	generating propellant-free aerosols containing a pharmacologically active agent, wherein the active ingredient is taken from the group fenoterol, Ipratropium bromide, Berotec, Atrovent, Berodual, Atrovent, Berotec, salbutamol, Combivent, Atrovent, salbutamol, Ba 679 Br, BEA 2108 Br or Oxivent, useful for treating obstructive lung diseases, particularly asthma. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.
47	Sanofi-Synthelabo Akzo Nobel	FR 9800515.19 19.1.1998	1999/0054 16.1.1999 Pub Date. 9/2007	23982 27.2.2008	15.1.2019	<i>Synthetic polysaccharides, process for their preparation and pharmaceutical compositions containing them</i> The present invention relates to synthetic polysaccharides in acidic form and to pharmaceutically acceptable salts thereof the anionic form of which corresponds to one of the formula (I) to (v) defined in claim these polysaccharides can be used in the treatment of pathologies related to a coagulation dysfunction.	<i>Patent Type: Product (Compound)</i> This patent covers synthetic polysaccharides in acidic form of heparin and their pharmaceutical compositions. The compounds are useful for treating and preventing thrombosis of either the arterial or venous origin. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.
48	Eli Lilly & Co	US 60/069722 16.12.1997	1998/1540 14.12.1998	23983 27.2.2008	13.12.2018	<i>Arylpiperazines having activity at the serotonin 1a receptor</i> A series of aryl piperazine	<i>Patent Type: Product (Compound)</i> This patent covers aryl piperazine compounds, for alleviating the symptoms of


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
		US 60/069791 16.12.1997 US 60/089589 17.6.1998	Pub Date. 9/2007			compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal.	nicotine and tobacco withdrawal. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.
49	Merck & Co Inc	US 60/261933 16.1.2001 US 60/293440 24.5.2001	2002/0034 21.01.2002 Pub Date. 10/2005	23993 10.3.2008	11.1.2022	<i>Improved process for carbapenem synthesis</i> A process for synthesizing a compound represented by formula I: or a pharmaceutically acceptable salt thereof, wherein deprotection is conducted using a prerduced metal catalyst is disclosed.	<i>Patent Type: Process</i> The patent claims a process for synthesising carbapenem intermediates and compounds, useful in the treatment of bacterial infections.
50	Galena AS	GB 9919288.2 17.8.1999	2000/1069 19.8.2000 Pub Date. 11/2007	23994 10.3.2008	18.8.2020	<i>Pharmaceutical compositions for oral and topical administration</i> A method of increasing viscosity of a pharmaceutical formulation for oral or topical administration comprises the steps of combining: a) an effective amount of one or more hydrophobic active ingredients; b) 5 to 50 % of one or more compounds selected from polyglycerol esters of fatty acids with 6-15 glycerol units; c) 5 to 50 % of one or more	<i>Patent Type: Product and Method (Formulation)</i> The patent covers a pharmaceutical formulation and method for selected cyclosporins, taxoids and taxanes. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						compounds selected from polyglycerol esters of fatty acids and/or unsaturated fatty acids with 2-12 glycerol units; d) 5 to 50 % of one or more compounds selected from triglyceride macrogol glycerol esters, partial glycerides or fatty acids or macrogol esters of fatty acids and concurrently the ratio between components b) and d) is from 0.1 : 1 to 10 : 1; and wherein upon dilution with water 1 : 1 by volume the viscosity of the formulation increases by at least 5 times in comparison to the undiluted composition.	
51	Sigma-Tau Industrie Farmaceutiche Riunite SPA Istituto Nazionale Per Lo Studio E La Cura Dei Tumori	EP 99830124.6 9.3.1999	2000/0293 7.3.2000 Pub Date. 11/2007	23999 19.3.2008	6.3.2020	<i>Camptothecin derivatives having antitumor activity</i> Camptothecin derivatives of camptothecin of formula (I):	<i>Patent Type: Product (Compound)</i> The patent covers derivative compounds of camptothecin useful as antitumor drugs. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						 <p>(I)</p> <p>wherein the groups R₁, R₂ and R₃ are as defined in the description are disclosed. The compounds of formula (I) are endowed with antitumor activity and show a good therapeutic index. Processes for the preparation of the compounds of formula (I) and their use in the preparation of medicaments useful in the treatment of tumors, viral infections and antiplasmodium falciparum are also disclosed.</p>	
52	Pfizer Products Inc	US 60/083441 29.4.1998	1999/0482 29.4.1999	24000 19.3.2008	28.4.2019	<i>N</i> -(3-ethynylphenylamino) 6,7-bis (2-methoxyethoxy) -4-quinazolinamine mesylate anhydrate and monohydrate	<i>Patent Type: Product (Compound)</i> This patent claims the anhydrous and hydrate (polymorphic) forms of the

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
			Pub Date. 11/2007			<p>The present invention relates to the anhydrous and hydrate forms of N-(3-ethynylphenyl)-6,7-bis (2-methoxyethoxy)4-quinazolinamine mesylate. The invention also relates to pharmaceutical compositions containing N- (3-ethynylphenyl)-6,7-bis(2-methoxyethoxy) -4-quinazolinamine mesylate and to methods of treating hyperproliferative disorders, such as cancer, by administering N- (3-ethynylphenyl)-6,7- bis(2-methoxyethoxy)-4- quinazolinamine mesylate.</p>	<p>compound erlotinib mesylate for treating hyperproliferative disorders, such as cancer.</p> <p>This patent covers polymorphic forms of the marketed product Tarceva (erlotinib), but is not listed on the US FDA Orange Book for the product.</p>
53	Pfizer Products Inc	US 60/089229 15.6.1999	1999/0718 15.7.1999 Pub Date. 10/2007	24008 19.3.2008	14.6.2019	<p><i>Ziprasidone formulations</i></p> <p>Composition comprising crystalline ziprasidone free base or crystalline ziprasidone hydrochloride particles having a mean particle size less than 25 um and a pharmaceutically acceptable carrier are substantially bioequivalent and can be used to treat psychoses such as schizophrenia.</p>	<p><i>Patent Type: Product (Compound and Composition)</i></p> <p>This patent claims a composition comprising a free base or crystalline form of ziprasidone hydrochloride monohydrate.</p> <p>This patent relates to the marketed product Geodon, used for treating symptoms of schizophrenia and bi-polar disorders.</p>
54	Sanofi-Synthelabo	FR 9807464 15.6.1998	0710/1999 14.6.1999	24015 24.3.2008	13.6.2019	<p><i>Polymorphic form of clopidogrel hydrogen sulfate</i></p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent covers the crystalline form of</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
			Pub Date. 11/2007			The invention relates to a novel polymorphic orthorhombic hydrogenosulphate or (+)-(S)- alpha - (2 -chlorophenyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridinyl-5-methyl acetate hydrogenosulphate form and to a method for the production thereof.	clopidogrel hydrogen sulfate (Form 2). The patent relates to the marketed product Plavix, used to prevent strokes and heart attacks, and blood clots that may cause such attacks.
55	Smithkline Beecham Corporation	US 60/110903 4.12.1998	1999/1542 2.12.1999 Pub Date. 11/2007	24025 26.3.2008	1.12.2019	<i>Vitronectin receptor antagonist</i> A compound of formula (I) is disclosed which is a vitronectin receptor antagonist and is useful in the treatment of osteoporosis or a pharmaceutically acceptable salt thereof. 	<i>Patent Type: Product (Compound)</i> This patent covers a pharmaceutically active compound and compositions which inhibit the vitronectin receptor and is useful for the treatment of inflammation, cancer and cardiovascular disorders, such as atherosclerosis and restenosis, and diseases wherein bone resorption is a factor, such as osteoporosis. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.
56	Janssen Pharmaceutica NV	EP 99202087.5 28.6.1999 EP 00200452.1 11.2.2000	2000/0833 27.6.2000 Pub Date. 11/2007	24026 26.3.2008	26.6.2020	<i>Respiratory syncytial virus replication inhibitors</i> The present invention is concerned with benzimidazoles and imidazopyridines having antiviral activity in particular they have an inhibitory activity on the replication of the respiratory syncytial virus. It	<i>Patent Type: Method of Use</i> This patent claims the use a prodrug, N-oxide and stereochemically isomeric form of benzimidazole compounds with antiviral activity. This patent does not appear to relate to a marketed product as listed on the US

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						further concerns their preparation and compositions comprising them as well as their use as a medicine.	FDA Orange Book.
57	Bristol Myers Squibb Co	US 60/135265 21.5.1999 US 60/193727 31.3.2000	2000/0652 Pub Date. 10/2007	24027 26.3.2008	19.5.2020	<p><i>Pyrrolotriazine inhibitors of kinases</i></p> <p>The present invention provides compounds of formula (I)</p>  <p style="text-align: right;">(I)</p> <p>and pharmaceutically acceptable salts thereof. The formula (I) compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula (I) compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>The patent covers compounds that inhibit tyrosine kinase activity, useful as anti-cancer agents as well as for diseases other than cancer that are associated with signal transduction pathways operating through growth factor receptors such as VEGFR-2.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>
58	Bristol Myers Squibb Co	US 60/065195 12.11.1997	1998/1406 12.11.1998	24028 26.3.2008	11.11.2018	<p><i>Aminothiazole inhibitors of cyclin dependent kinases</i></p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent covers protein kinase inhibitors useful in the treatment and prevention of</p>


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
			Pub Date. 11/2007			<p>Compounds of formula (I)</p>  <p>and pharmaceutically acceptable salts thereof. As used in formula (I), and throughout the specification, the symbols have the following meanings: R1 and R2 are independently hydrogen, fluorine or alkyl; R3 is aryl or heteroaryl. The compounds of formula (I) are protein kinase inhibitors and are useful in the treatment and prevention of proliferative diseases, for example cancer, inflammation and arthritis.</p>	<p>proliferative diseases, for example, cancer, inflammation and arthritis. They may also be useful in the treatment of neurodegenerative diseases such as Alzheimer's disease, cardiovascular diseases, viral diseases and fungal diseases.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>
59	Chiesi Farmaceutici SPA	EP 01117071.0 2.7.2001	2002/0744 29.6.2002 Pub Date. 11/2007	24019 25.3.2008	28.6.2022	<p><i>Optimised formulation of tobramycin for aerosolization</i></p> <p>The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be</p>	<p><i>Patent Type: Product (Formulation)</i></p> <p>This patent claims an aerosol formulation of tobramycin, useful for treating various forms of bacterial infections.</p> <p>Various generic products exist comprising tobramycin.</p> <p>This patent does not appear to relate to a</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium <i>Pseudomonas aeruginosa</i> associated to lung diseases such as cystic fibrosis.	marketed product as listed on the US FDA Orange Book.
60	Almirall Prodesfarma SA	ES 9701670	1998/0889 29.7.1998 Pub Date. 9/2007	24041 3.4.2008	28.7.2018	<p><i>New heterocyclic compounds</i></p> <p>Heterocyclic compounds of formula (I),</p>  <p style="text-align: right;">(1)</p> <p>wherein R1 represents a hydrogen atom or a -(CH₂)_m-Y group, wherein m is an integer from 0 to 4 and Y represents an alkyl, haloalkyl, alkoxy, alkoxycarbonyl, C3-C7 cycloalkyl, norbornyl or phenylalkenyl group, or an aromatic group which aromatic group Y may optionally be substituted by one or more halogen atoms; R2 represents an aromatic group which aromatic</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent covers triazolo-phthalazine derivative compounds are useful in the treatment of inflammatory and allergic processes such as asthma, non-steroidal antiinflammatory drugs-induced gastrointestinal damage and atopic dermatitis.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						group may optionally be substituted by one or more halogen atoms or alkyl, alkoxy, C3-C6 cycloalkoxy, methylenedioxy, nitro, dialkylamino or trifluoromethyl groups; and R3 represents a hydrogen or halogen atom or an alkyl group, and pharmaceutically acceptable salts thereof, processes for preparing the same and their use in medical treatment.	
61	Astra Aktiebolag	SE 9702000.2 28.5.1997	1998/0568 25.5.1998 Pub Date. 10/2007	24044 13.4.2008	24.5.2018	<p><i>Pharmaceutical formulation of omeprazole</i></p> <p>An enteric coated oral pharmaceutical formulation comprising as active ingredient a compound selected from the group of omeprazole, an alkaline salt of omeprazole, the (-)-enantiomer of omeprazole and an alkaline salt of the (-)-enantiomer of omeprazole, wherein the formulation comprises a core material of the active ingredient and optionally an alkaline reacting</p>	<p><i>Patent Type: Product (Formulation)</i></p> <p>This patent claims an enteric coated oral pharmaceutical formulation comprising omeprazole, and alkaline salt of omeprazole, the (-)-enantiomer of omeprazole and an alkaline salt of the (-)-enantiomer of omeprazole.</p> <p>Omeprazole is used to treat gastroesophageal reflux disease (GERD), a condition in which backward flow of acid from the stomach causes heartburn and possible injury of the esophagus (the</p>


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						<p>compound, the active ingredient is in admixture with a pharmaceutically acceptable excipient, such as for instance a binding agent, and on said core material a separating layer and an enteric coating layer. A hydroxypropyl methylcellulose (HPMC) of low viscosity with a specific cloud point is used in the manufacture of pharmaceutical formulations. Furthermore, the application describes the processes for their preparation and the use of the claimed formulations in medicine.</p>	<p>tube between the throat and stomach). This patent does not appear to relate to any of the omeprazole products marketed by Astra Zeneca (e.g. Prilosec and Nexium) as listed on the US FDA Orange Book.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p> <p>Omeprazole is available in generic form from a number of manufacturers.</p>
62	Hoechst Marion Roussel Inc	US 09/042251 13.3.1998 US 09/250718 16.2.1999	1999/0233 10.3.1999 Pub Date. 11/2007	24052 13.4.2008	9.3.2019	<p><i>Novel processes for the preparation of (r)-a (2,3-demethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethapnol</i></p> <p>The present invention provides various processes for the preparation of (R)- alpha -(2,3-dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent claims various investigational compounds and processes for their preparation.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
63	F Hoffmann-La Roche	EP 9911818.1 13.9.1999	2000/1159 12.9.2000 Pub Date. 1/2008	24117 6.7.2008	11.9.2020	piperidinemethanol. <i>Dispersion formulations containing lipase inhibitors</i> The present invention relates to pharmaceutical compositions comprising at least one inhibitor of lipases, preferably an inhibitor of gastrointestinal and pancreatic lipases, e.g. orlistat, at least one surfactant and at least one dispersant.	<i>Patent Type: Product (Pharmaceutical Composition)</i> This patent covers pharmaceutical compositions comprising a lipase inhibitor such as lipstatin and orlistat, a surfactant and dispersant. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.
64	Zeneca Limited	GB 9611328.7 31.5.1996	1997/0473 28.5.1997 Pub Date. 1/2008	24118 6.7.2008	27.5.2017	<i>Pharmaceutical Compositions</i> The invention relates to sustained release formulations comprising 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo[b,f][1,4]thiazepine or a pharmaceutically acceptable salt thereof, to methods of treating psychotic states and hyperactivity utilizing the sustained release formulations and to a process for preparing the sustained release formulations.	<i>Patent Type: Product (Formulation)</i> This patent covers a sustained release formulation comprising a gelling agent and the compound quetiapine, useful for treating schizophrenia. The base patent of quetiapine expires on 2011/2012 and is marketed by Astrazeneca under the name Seroquel. This patent does not appear on the US FDA Orange Book patent listings for the product Seroquel.
65	Pfizer Research and Development Company	GB 9612514.1 14.6.1996	1997/0540 12.6.1997 Pub Date. 2/2008	24123 6.7.2008	11.6.2017	<i>Process for Preparing Sildenafil</i> A process for the preparation of a compound of formula (I) also known as sildenafil which comprises	<i>Patent Type: Process</i> This patent claims a process for preparing the compound sildenafil and its intermediates.


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						cyclisation of a compound of formula (II) 	Sildenafil is used to treat erectile dysfunction (marketed as Viagra) and to improve the ability of people with pulmonary arterial hypertension to exercise (marketed as Revatio). This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.
66	Menarini International Operations Luxembourg SA	IT FI 2001A000230 29.11.2001	2002/1281 27.11.2002 2.2008	24124 7.7.2008	26.11.2022	<i>Pharmaceutical compositions for the treatment of type-II diabetes mellitus</i> Orally administrable pharmaceutical compositions in the form of tablets, comprising glibenclamide and metformin, or pharmaceutically acceptable salts thereof, as active ingredients, maintained separate from one another within the same composition, are described for the treatment of type-II diabetes mellitus.	<i>Patent Type: Product (Formulation)</i> The patent covers pharmaceutical formulations for oral administration in tablet form comprising glibenclamide and metmorfin for the treatment of Type II diabetes. It appears the base compounds glibenclamide and metamorfin are no longer under patent. This patent does not appear to relate to a

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
							marketed product as listed on the US FDA Orange Book.
67	Merck & Co Inc Merck Sharp & Dohme Ltd	US 60/373734 18.4.2002	2003/0353 19.4.2003 Pub Date. 2/2008	24127 8.7.2008	18.4.2023	<p><i>Process for 5-((2(R)-(1(R)(3,5 Bis (Trifluoromethyl)phenyl)ethoxy)-3(S)-(4-Fluorophenyl)-4-Morpholinyl)methyl)-1,2-Dihydro-3H-1,2,4-triazol-3-one</i></p> <p>The present invention is concerned with a novel process for the preparation of the compound 5-[[2(R)-[1(R)-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(S)-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one. This compound is useful as a substance P (neurokinin-1) receptor antagonist. In particular, the compound is useful e.g., in the treatment of psychiatric disorders, inflammatory diseases and emesis</p>	<p>Patent Type: Process</p> <p>This patent covers a process for preparing the compound Aprepitant.</p> <p>Aprepitant is marketed as Emend, to prevent nausea and vomiting after chemotherapy.</p>
68	Zeneca Limited	GB 9508538.7 27.4.1995	1996/0538 23.4.1996 Pub Date. 3/2008	24134 6.8.2008	22.4.2016	<p><i>Quinazoline derivatives</i></p> <p>The invention concerns quinazoline derivatives of the formula (I) wherein n is 1, 2 or 3 and each R<2> is independently halogeno, trifluoromethyl or (1-4C)alkyl; R<3></p>	<p>Patent Type: Product (Compound)</p> <p>This patent covers quinazoline derivative compounds related to gefitinib.</p> <p>Gefitinib is marketed as Iressa, to treat certain types of cancer.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						<p>is (1-4C)alkoxy; and R<1> is di-[(1-4C)alkyl]amino-(2-4C)alkoxy, pyrrolidin-1-yl-(2-4C)alkoxy, piperidino-(2-4C)alkoxy, morpholino-(2-4C)alkoxy, piperazin-1-yl-(2-4C)alkoxy, 4-(1-4C)alkylpiperazin-1-yl-(2-4C)alkoxy, imidazol-1-yl-(2-4C)alkoxy, di-[(1-4C)alkoxy-(2-4C)alkoxy]amino-(2-4C)alkoxy, thiamorpholino-(2-4C)alkoxy, 1-oxothiamorpholino-(2-4C)alkoxy or 1,1-dioxothiamorpholino-(2-4C)alkoxy, and wherein any of the above-mentioned R<1> substituents comprising a CH₂ (methylene) group which is not attached to a N or O atom optionally bears on said CH₂ group a hydroxy substituent; or pharmaceutically-acceptable salts thereof; processes for their preparation, pharmaceutical compositions containing them, and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of proliferative disease such as cancer.</p>	
69	Pfizer Inc	US 60/019204 7.5.1996	1997/0378 4.5.1997	24135 6.8.2008	3.5.2017	<p><i>Inclusion complexes of aryl heterocyclic salts</i></p> <p>Compositions of matter comprising a</p>	<p><i>Patent Type: Product (Composition)</i></p> <p>This patent claims a composition of matter comprising a pharmaceutically acceptable</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
			Pub Date. 3/2008			pharmaceutically acceptable salt of an aryl-heterocyclic compound, such as ziprasidone, in a cyclodextrin. Preferred cyclodextrins are SBECD and HPBCD. The composition can comprise a dry mixture, a dry inclusion complex or an aqueous solution. The salt/cyclodextrin inclusion complex preferably provides an amount of ziprasidone of at least 2.5 mgA/ml when the complex is dissolved in water at 40 % w/v. A variety of ziprasidone salts are preferred, including the mesylate, esylate, besylate, tartrate, napsylate, and tosylate.	salt, cyclodextrin and the compound ziprasidone. This patent relates to the marketed product Geodon (ziprasidone), used for treating symptoms of schizophrenia.
70	Schering Corporation	US 09/305226 4.5.1999	2000/0563 2.5.2000 Pub Date. 3/2008	24136 6.8.2008	1.5.2020	<p><i>Piperazine derivatives useful as ccr5 antagonists</i></p> <p>The use of CCR5 antagonists of formula (I):</p>  <p style="text-align: right;">(I)</p> <p>or a pharmaceutically acceptable salt thereof, wherein: R is optionally</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>The patent claims piperazine derivative compounds and their pharmaceutical compositions, useful for treating HIV.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						<p>substituted phenyl, pyridyl, thiophenyl or naphthyl; R<1> is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.</p>	

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
71	Pfizer Inc	GB 0014046.7 26.5.2000 GB 0015835.2 27.6.2000	0535/2001 22.5.2001 Pub Date. 3/2008	24137 6.8.2008	21.5.2021	<p><i>Tropane derivatives useful in therapy</i></p> <p>The present invention provides compounds of the formula (I):</p>  <p>wherein R1 is C3-6 cycloalkyl optionally substituted by one or more fluorine atoms, or C1-6 alkyl optionally substituted by one or more fluorine atoms, or C3-6 cycloalkylmethyl optionally ring-substituted by one or more fluorine atoms; and R2 is phenyl optionally substituted by one or more fluorine atoms, to pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds.</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent covers various tropane derivative compounds, including maraviroc.</p> <p>This patent relates to the marketed product Selzentry (maraviroc) for treating HIV/AIDS.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
72	Warner Lambert Company	US 60/178359 27.1.2000 US 60/190427 17.3.2000	2001/0073 24.1.2001 Pub Date. 2/2008	24138 6.8.2008	23.1.2021	<i>Asymmetric synthesis of pregabalin</i> This invention provides a method of making (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid (pregabalin) or a salt thereof via an asymmetric hydrogenation synthesis. Pregabalin is useful for the treatment and prevention of seizure disorders, pain, and psychotic disorders. The invention also provides intermediates useful in the production of pregabalin.	<i>Patent Type: Method/Process</i> This patent claims a method for preparing the S-enantiomer compound of pregabalin, used to treat neuropathic pain. Pregabalin is marketed as Lyrica.
73	Boehringer Ingelheim Pharma KG	DE 10050635.6 12.10.2000	2001/1059 9.10.2001 Pub Date. 2/2008	24139 6.8.2008	8.10.2021	<i>New inhalable powder containing tiotropium</i> The invention relates to tiotropium-containing powdery preparations to be inhaled, to methods for producing them and to the use thereof in the production of medicaments for treating respiratory diseases, especially for treating COPD (chronic obstructive pulmonary disease) and asthma.	<i>Patent Type: Product (Formulation)</i> This patent covers an inhalable powder containing tiotropium. This patent relates to the marketed product Spiriva, used for treating wheezing and shortness of breath in patients with chronic obstructive pulmonary disease.



	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
74	Astra Aktiebolag	SE 0/9801992 4.6.1998	1999/0656 3.6.1999 Pub Date. 2/2008	24140 6.8.2008	2.6.2019	<i>New 3-aryl-2-hydroxypropionic acid derivative</i> A novel 3-aryl-2-hydroxypropionic acid derivative, a process and intermediate for its manufacture, pharmaceutical preparations containing it and the use of the compound in clinical conditions associated with insulin resistance.	<i>Patent Type: Product (Compound)</i> This patent covers derivative compounds of 3-aryl-2-hydroxypropionic acid. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.
75	F Hoffmann-La Roche	EP 00113535.9 27.6.2000	0680/2001 24.6.2001 Pub Date. 2/2008	24141 6.8.2008	23.6.2021	<i>Method for preparing a composition</i> The present invention relates to a method for the preparation of compositions, preferably pharmaceutical compositions, in form of expanded, mechanically stable, lamellar, porous, sponge-like or foam structures out of solutions and dispersions. This method comprises the steps of a) preparing a solution or a homogeneous dispersion of a liquid and a compound selected from the group consisting of one or more pharmaceutically active compounds, one or more pharmaceutically suitable excipients, and mixtures thereof, followed by b) the expansion of the solution or the homogeneous dispersion without boiling. The	<i>Patent Type: Method/Process</i> The patent covers a method for preparing a pharmaceutical composition comprising the steps of a) preparing a solution or a homogeneous dispersion of a liquid and a compound selected from the group consisting of one or more pharmaceutically active compounds (including oseltamivir), one or more pharmaceutically suitable excipients, and mixtures thereof, followed by b) expansion of the solution or homogeneous dispersion without boiling. This patent claims a method for preparing a composition including oseltamivir, which is used for treating avian flu.


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						invention also relates to the compositions, their further processing and any corresponding dosage forms obtainable by the above method.	
76	Boehringer Ingelheim Pharma KG	DE 10050621.6 12.10.2000	2001/1058 9.10.2001 Pub Date. 2/2008	24142 6.8.2008	8.10.2021	<p><i>Crystalline monohydrate, process for the preparation thereof and the use thereof for preparing a pharmaceutical composition</i></p> <p>The invention relates to a crystalline monohydrate of (1 alpha ,2 beta ,4 beta ,5 alpha ,7 beta)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatrycyclo[3.3.1.0 2,4]nonane bromide, to a method for producing the same, and to the use thereof in the production of a medicament, especially for producing a medicament that has an anticholinergic effect.</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent claims the crystalline form tiotropium bromide monohydrate.</p> <p>This patent relates to the marketed product Spiriva, used to treat wheezing and shortness of breath in patients suffering chronic obstructive pulmonary disease.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
77	Pfizer Inc	GB 9922963.5 28.9.1999	2000/1216 25.9.2000 Pub Date. 2/2008	24143 6.8.2008	24.9.2020	<p><i>Polymorphic Salt</i></p> <p>The present invention is concerned with a crystalline, polymorphic form of a compound of formula (I):</p>  <p>characterised by a powder X-ray diffraction pattern obtained using copper K-alpha radiation (gamma = 0.15046 nm) which shows main peaks at 9.28, 10.38, 11.37, 12.40, 16.84, 17.46, 17.53, 17.78, 17.98, 19.48, 20.70, 21.29, 21.45, 22.21, 22.64, 23.08, 25.20 and 25.79. The invention also relates to processes for the preparation of said form, to pharmaceutical compositions containing same and to its use in medicine, particularly the treatment of conditions for which an agonist of 5-HT₁ receptors is indicated, for example, migraine.</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent covers the polymorphic form of the hemisulphate salt eletriptan.</p> <p>Eletriptan is marketed as Relpax for treating migraine headaches. This patent is not listed on the US FDA Orange Book for the product Relpax.</p>


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
78	Boehringer Ingelheim Pharma KG	DE 19706229.6 18.2.1997 DE 19751939.3 24.11.1997	1998/0184 17.2.1998 Pub Date. 2/2008	24144 6.8.2008	16.2.2018	<p><i>Disubstituted bicyclic heterocycles their preparation and their use as medicaments</i></p> <p>The invention relates to new disubstituted bicyclic heterocycles of the general formula (I): Ra-A-Het-B-Ar-E, in which A, B, Ar, Het and Ra are defined as in claim 1. The invention also relates to their tautomers, their stereoisomers, their mixtures, and their salts, which have valuable properties. The compounds of the above general formula (I), in which E is a cyano group, thus represent valuable intermediate products for the production of the other compounds of the general formula (I). Furthermore, the compounds of the above general formula (I), in which E stands for a RbNH-C(=NH)-group, have valuable pharmacological properties, in particular in inhibiting thrombin and prolonging thrombin time.</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent covers disubstituted bicyclic heterocycles with anti-thrombin properties.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
79	Smithkline Beecham	GB 9712854.0 18.6.1997	1998/0689 17.6.1998 Pub Date. 2/2008	24157 20.8.2008	16.6.2018	<p><i>Novel method of treatment</i></p> <p>A method for the treatment and/or prophylaxis of diabetes mellitus conditions associated with diabetes mellitus and certain complications thereof in a mammal which method comprises administering an effective non toxic and pharmaceutically acceptable amount of an insulin sensitiser and a biguanide antihyperglycaemic agent to a mammal in need thereof and a pharmaceutical composition comprising an insulin sensitiser and a biguanide antihyperglycaemic agent.</p>	<p><i>Patent Type: Method of Use</i></p> <p>This patent covers a method of treating diabetes mellitus by administering an effective non-toxic and pharmaceutically acceptable amount of insulin sensitiser and insulin secretagogue (which could include the compounds glibenclamide, glipizide, gliclazide, glimepiride, tolazamide or tolbutamide).</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>
80	Smithkline Beecham	US 98248933 12.11.1998	1999/1430 11.11.1999 Pub Date. 2/2008	24158 20.8.2008	10.11.2019	<p><i>Novel method of treatment</i></p> <p>A method for the treatment of type 2 diabetes mellitus and conditions associated with diabetes mellitus, which method comprises the administration to a human or non-human mammal in need thereof of an effective non-toxic amount of an insulin sensitiser so as to provide a plasma concentration of the insulin sensitiser of at least a threshold level (the Threshold Plasma Concentration) from within range of effective plasma levels of the insulin sensitiser</p>	Information not available

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						compositions for use in such method and methodology for determining plasma concentrations of active agent use in such methods.	
81	Otsuka Pharmaceutical Co	JP 08/258533 30.9.1996	1997/0997 25.9.1997 Pub Date. 2/2008	24160 20.8.2008	24.9.2017	<p><i>Agent for inhibition of cytokine production and agent for inhibition of cell adhesion</i></p> <p>The present invention provides an agent for inhibiting cytokine production or cell adhesion, comprising at least one compound selected from the group consisting of thiazole derivatives represented by general formula (1), wherein R1 is a phenyl group which may have a lower alkoxy group(s) as a substituent(s) on the phenyl ring, and R2 is a group represented by general formula (2), wherein R3,s, which may be the same or different, are each a carboxyl group, a lower alkoxy group or the like, and salts thereof.</p> <div style="text-align: center;">  (1)  (2) </div>	<p><i>Patent Type: Product (Compound)</i></p> <p>The patent claims compounds for inhibiting cytokine production and which are useful as anti-cancer agents.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
82	Otsuka Pharmaceutical Co Ltd	JP 9-222431 19.8.1997	1998/0942 13.8.1998 Pub Date. 3/2008	24161 20.8.2008	12.8.2018	<p><i>Carbostyryl derivatives</i></p> <p>The present invention provides an agent for inhibiting skin erythema and/or skin pigmentation, containing at least one selected from the group consisting of the carbostyryl derivative and salt thereof represented by general formula (1):</p>  <p style="text-align: right;">(1)</p> <p>wherein R1 is a hydrogen atom, a lower alkyl group or the like; R2 is a hydrogen atom, a lower alkyl group, a lower alkoxy group or the like; R3 and R4 are lower alkyl groups which may have hydroxyl groups as substituents or the like; the carbon-carbon bond between 3- and 4-positions in the carbostyryl skeleton is a single bond or double bond.</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>The patent covers a carbostyryl derivatives and their salts, useful for treating skin erythema or pigmentation.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
83	Prof. Dr Ahmed Mohamed Aly Massoud		1996/0380 2.5.1996 Pub Date. 3/2008	24149 17.8.2008	1.5.2016	<p><i>Drug for treatment of bilharziasis</i></p> <p>Extraction of volatile oils and resins from Myrrk and use of each and both together for treatment of Bilharziasis and Fascioliasis: 1) preparation and separation of volatit oils: water and steam distillation is employed, the drug is ground and immediately covered with a layer of water asteam is passed through the mixture by pipes. The volatile oil is condensed in the condensing chamber. The oil layers are separate from the aqueous layer</p> <p>2.Preparation and separation of resins the powdered drug after separation of volatite oil component is exhansted with ethanol. Alcohol extact is evaparated and the precipitated resin is collected washed and dried.</p>	<p><i>Patent Type: Product (Composition)</i></p> <p>This patent covers a pharmaceutical composition for treating schistosoma using oils extracted from the stem of the plant commiphora molmol.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>
84	Novartis AG	EP 01403339.3 21.12.2001	2002/1358 17.12.2002 Pub Date. 5/2008	24194 14.10.2008	16.12.2022	<p><i>5ht-a-partial agonist pharmaceutical compositions</i></p> <p>A solid pharmaceutical composition for oral administration comprising tegaserod in base or salt form in an amount of up to 10% by weight a bulking agent in an amount of 70 to 90% by weight a disintegrant in an</p>	<p><i>Patent Type: Product (Composition)</i></p> <p>The patent claims a solid composition for oral administration of tegaserod, useful for the prevention and treatment of gastrointestinal motility disorders e.g. irritable bowel syndrome.</p> <p>Tegaserod is marketed under the brand</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						amount of less than 14% by weight a glidant and a lubricant.	<p>name Zelnorm.</p> <p>This patent does not appear to be listed on the US FDA Orange Book for the product Zelnorm.</p>
85	Pfizer Inc	US 60/009469 28.12.1995	1996/1177 24.12.1996 Pub Date. 5/2008	24195 14.10.2008	23.12.2016	<p><i>Heterocyclic compounds</i></p> <p>This invention is directed to compounds of formula (I):</p>  <p>and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretagogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent covers dipeptide compounds useful for the treatment of osteoporosis.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						<p>cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis. The compounds of the present invention are also useful in treating osteoporosis when used in combination with: a bisphosphonate compound such as alendronate; estrogen, premarin, and optionally progesterone; an estrogen agonist or antagonist; or calcitonin, and pharmaceutical compositions useful therefor. Further, the present invention is directed to pharmaceutical compositions useful for increasing the endogenous production or release of growth hormone in a human or other animal which comprises an effective amount of a compound of the present invention and a growth hormone secretagogue selected from GHRP-6, Hexarelin, GHRP-1, growth hormone releasing factor (GRF), IGF-1, IGF-2 or B-HT920. The invention is also directed to intermediates useful in the</p>	

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						preparation of compounds of formula (I).	
86	Eli Lilly & Co	US 60/146184 29.7.1999 US 60/147642 6.8.1999 US 60/149820 19.8.1999	2000/0954 26.7.2000 Pub Date. 4/2008	24196 14.10.2008	25.7.2020	<p><i>A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride</i></p> <p>A novel crystalline hydrate of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]-phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride (arxoxifene) is used for inhibition of disease states associated with estrogen deprivation including cardiovascular disease, hyperlipidemia, and osteoporosis; and inhibition of other pathological conditions such as endometriosis, uterine fibrosis, estrogen-dependent cancer (including breast and uterine cancer), prostate cancer, benign prostatic hyperplasia, CNS disorders including Alzheimer's disease, prevention of breast cancer, and up-regulating ChAT.</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent covers a crystalline form of arxoxifene. Arxoxifene is a nonsteroidal mixed estrogen antagonist /agonist, useful for, inter alia, lowering serum cholesterol and for inhibiting hyperlipidemia, osteoporosis, estrogen dependent cancers including breast and uterine cancer, endometriosis, CNS disorders including Alzheimer's disease, aortal smooth muscle cell proliferation, and restenosis.</p> <p>Arxoxifene was pulled from clinical trial phase III.</p>
87	Astra Aktiebolag	SE 9600086/4 10.1.1996	1997/0017 7.1.1997 Pub Date. 4/2008	24197 14.10.2008	6.1.2017	<p><i>New Manufacturing Process</i></p> <p>A method for the manufacture of felodipine by reaction of dichlorobenzylidene and ethyl 3-</p>	<p><i>Patent Type: Method/Process</i></p> <p>This patent covers a method for the manufacture of felodipine.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						aminocrotonate using an alcohol as solvent.	<p>Felodipine is marketed under the trade name Plendil for treating high blood pressure.</p> <p>Felodipine is available in generic form.</p>
88	American Home Products Corporation	US 60/014006 25.3.1996	1997/0182 11.3.1997 Pub Date. 4/2008	24198 14.10.2008	10.3.2017	<p><i>Extended release formulation</i></p> <p>This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets.</p>	<p><i>Patent Type: Product (Formulation)</i></p> <p>This patent covers an extended release formulation of venlafaxine hydrochloride.</p> <p>This patent relates to the marketed product Effexor, used for treating depression.</p> <p>Venlafaxine hydrochloride is also available in generic form.</p>
89	Smithkline Beecham Plc	GB 9712857.3 18.6.1997	1998/0690 17.6.1998 Pub Date. 6/2008	24199 19.10.2008	16.6.2018	<p>Novel method of a treatment</p> <p>A method for the treatment and/or prophylaxis of diabetes mellitus conditions associated with diabetes mellitus and certain complications thereof in a mammal which method</p>	<p><i>Patent Type: Method of Treatment/Use</i></p> <p>The patent claims a method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitiser and a biguanide antihyperglycaemic agent to a mammal in need thereof and a pharmaceutical composition comprising an insulin sensitiser and a bi guanide antihyp erglycaemic agent.	pharmaceutically acceptable amount of an insulin sensitiser (rosiglitazone maleate) and a biguanide antihyperglycaemic agent (metamorfin and metamorfin hydrochloride), to a mammal in need thereof. This patent relates to the marketed product Avandamet.
90	Smithkline Beecham Plc Smithkline Beecham Cork Ltd		2000/0510 22.4.2000 Pub Date. 6/2008	24200 19.10.2008	21.4.2020	<i>Novel pharmaceutical</i> A polymorphic form of 5-{4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzylthiazolidine-2,4-dione,maleic acid salt (the "polymorph) characterised in that it provides : (i) an infra red spectrum containing peaks at 176,3,912,856 and 709cm-1;andlor (ii) a Raman spectrum containing peaks at 1762,1284,912 and 888cm-1;atdlor (iii) a solid-state I3C nuclear magnetic resonance spectrum containing peaks at 111.0,113.0,119.8,129.1,r30.9,131.9,13407,139.7,146.5,152.7,157.5,16t5,171.0, I 8.7ppm;andlor (iv) an X-ray powder diffraction(XRPD)pattem	<i>Patent Type: Product (Compound)</i> This patent covers a polymorphic form of rosiglitazone maleate, useful for treating type II diabetes along with other medications. This patent relates to the marketed product Avandia.


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						which gives calculated lattice spacing at 5 .87,5 .30,4.69,4.09,3. 8 8,3.6 1,3 .53 and 3.46 Angstroms;a process for preparing such a compound a pharmaceutical composition containing such a compound and the use of such a compound in medicine.	
91	LG Chemical Ltd	KR 2000-15091 24.3.2000	2001/0295 24.3.2001 Pub Date. 4/2008	24204 20.10.2008	23.3.2021	<i>A somatotropin composition with improved syringeability</i> The present invention relates to an improved somatotropin composition consisting of somatotropin having activity in vivo, at least one of lipid-soluble vitamins and at least one of pharmaceutically acceptable lubricants, which improves poor syringeability under cold temperature which has been a defect of the conventional somatotropin formulation using vitamins, and which shows at least the equivalent effect to that of the conventional formulation.	<i>Patent Type: Product (Composition)</i> This patent covers a composition comprising somatotropin that is injectable. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.
92	H Lundbeck A/S	DK PA20101164 31.7.2001	2002/0849 28.7.2002 Pub Date. 6/2008	24206 21.10.2008	27.7.2022	<i>Crystalline composition containing escitalopram</i> Crystalline particles of escitalopram oxalate with a particle size of at least	Patent Type: Product (Compound) This patents covers crystalline particles of escitalopram oxalate, used to treat depression.

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						40[micro]m is disclosed. Method for the manufacture of said crystalline particles and pharmaceutical compositions comprising said crystalline particles are also disclosed.	This patent relates to the marketed product Lexapro.
93	Les Laboratoires Servier	FR 0307118 13.6.2003	2004/0261 10.6.2004 Pub Date. 6/2008	24207 21.10.2008	9.6.2024	<p><i>New benzothiazine and benazothiadizine compounds, a process for their preparation and pharmaceutical compositions containing them</i></p> <p>Compounds of formula (I)</p> <p>Wherein: R1 represents hydrogen, a halogen or alkyl, Rru represents hydrogen or alkyl, R2 represents hydrogen, a halogen or hydroxy, A represents CR+Rs or NR4, & represents hydrogen, alkyl or cycloalkyl, R4 represents hydrogen or al\$, Or A represents nitrogen and, together with the adjacent - CH& - forms the ring Wherein m represents 1,2 or 3 .</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent covers derivatives of the compounds benzothiazine and benzothiadiazine, useful for the treatment and prevention of disorders associated with mnemocognitive age, anxiety or depressive syndromes, progressive neurodegenerative disease, Alzheimer's disease, Pick's disease, the chorea Huntington's, schizophrenia, the effects of acute neurodegenerative diseases, the effects of ischemia and the effects of epilepsy.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						<p>Rs represents hydrogen or a halogen. X is as defined in the description.</p> <p>Their isomers, and also addition salts thereof.</p>	
94	Otsuka Pharmaceutical Co Ltd	<p>JP 182504/2001 15.6.2001</p> <p>JP 4000871/2001 28.12.2001</p> <p>JP 111131/2002 12.4.2002</p>	<p>2002/0661 12.6.2002</p> <p>Pub Date. 5/2008</p>	<p>24184 8.10.2008</p>	11.6.2022	<p><i>Dry powder inhalation system for transpulmonary</i></p> <p>The present invention provides a novel dry powder inhalation system suitable for transpulmonary administration. The dry powder inhalation system of the invention characterized by using a combination of:</p> <p>a vessel housing a freeze-dried composition that contains a single dose of an active ingredient and has:</p> <ol style="list-style-type: none"> 1) a non powder cake like form 2) a disintegration index of 0.015 or more and 3) a property of becoming fine particles having a mean particle diameter of 10 microns or less or a fine particle fraction of 10% or more upon receipt of an air impact having an air speed of at least 1m/sec and an air flow rate of at least 	<p><i>Patent Type: Product (Formulation)</i></p> <p>This patent covers a dry powder inhalation system.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						17ml/sec; and a device comprising means capable of applying said air impact to the freeze-dried composition in said vessel and means for discharging the powder form freeze-dried composition that has been made into fine particles.	
95	Merck & Co. Inc	US 60/208017 26.5.2000	2001/0540 22.5.2001 Pub Date. 5/2008	24189 8.10.2008	21.5.2021	<p><i>5-chloro-3-(-4-methanesulfonylphenyl)-6-methyl-[2,3] bipyridinyl in pure crystalline form and process for synthesis</i></p> <p>This invention encompasses the Form V polymorph of Compound A of structural formula (A) which is useful in the treatment of cyclooxygenase-2 mediated diseases. The invention encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising the Form V polymorph of Compound A. The invention also encompasses a process for synthesizing the Form V polymorph of Compound A.</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent covers a polymorphic form of the investigational compound 5-chloro-3-(-4-methanesulfonylphenyl)-6-methyl-[2,3] bipyridinyl and a method for treating an inflammatory disease.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
96	The Rogosin Institute	US 09/188476 9.11.1998	1999/1400 8.11.1999 Pub Date. 6/2008	24212 28.10.2008	7.11.2019	<p><i>Compositions of restricted cancer cells which produce cancer cell proliferation suppressive materials and uses thereof</i></p> <p>Compositions of matter are described which contain restricted proliferative cells. When so restricted, the cells produce an unexpectedly high amount of material which suppresses cell proliferation. The phenomenon crosses cell type and species lines. Processes for making these compositions, and their use, are also described.</p>	<p><i>Patent Type: Product (Composition)</i></p> <p>The patent claims a composition containing restricted proliferative cells.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>
97	Eli Lilly & Co Lilly Industries	US 08/409566 24.3.1995 US 08/410474 24.3.1995	1996/0253 12.3.1996 Pub Date. 6/2008	24221 10.11.2008	20.3.2016	<p><i>Process for preparing olanzapine</i></p> <p>The invention provides methanol, ethanol, and 1-propanol solvates of olanzapine (formula (I)) and a process for using such solvates.</p>	<p>Patent Type: Product (Compound)</p> <p>This patent claims a crystalline mono methanol solvate form of olanzapine, useful for treating symptoms of schizophrenia.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p> <p>Olanzapine is available in generic form.</p>


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
98	Astra Aktiebolag	GB 9417084.2 24.8.1994 GB 954627.2. 8.3.1995	1995/0703 23.8.1995 Pub Date. 6/2008	24222 10.11.2008	22.8.2015	<p><i>Spiro-azabicyclic compounds useful in therapy</i></p> <p>There are provided new compounds of formula (I):</p>  <p>wherein R represents hydrogen or methyl; and n represents 1 or 2; or a pharmaceutically acceptable acid addition salt thereof, together with processes for preparing them, compositions containing them and their use in therapy. Compounds of formula (I) are expected to be useful in the treatment of psychotic disorders, intellectual impairment disorders and anxiety.</p>	<p>Patent Type: Product (Compound)</p> <p>This patent covers spiro azabiycyclic compounds useful for treatment of schizophrenia, nausea, migraine and Alzheimer disease.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>
99	Eli Lilly and Co	US 60/203235 8.5.2000	2001/0461 5.5.2001 Pub Date. 6/2008	24223 10.11.2008	4.5.2021	<p><i>Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene</i></p>	<p>Patent Type: Product (Formulation)</p> <p>The patent claims a pharmaceutical formulation comprising arzoxifene hydrochloride and a stabilising agent.</p>


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						<p><i>and salts thereof</i></p> <p>The present invention is directed to pharmaceutical formulations containing 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene or a salt thereof; stabilized to oxidation or other forms of decomposition by incorporation of a stabilizing agent selected from methionine, acetylcysteine, cysteine or salts thereof.</p>	<p>Arzoxifene hydrochloride was removed from phase II clinical trials.</p>
100	Astra Aktiebolag	SE 9702483 27.6.1997	1998/0742 24.6.1998 Pub Date. 6/2008	24224 10.11.2008	23.6.2018	<p><i>Omeprazole sodium salt</i></p> <p>This invention relates to a novel form of the sodium salt of 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl) methyl]sulfinyl]-1H-benzimidazole, known under the generic name of omeprazole sodium salt. This invention also relates to processes for its preparation of omeprazole sodium form B which is thermodynamically stable, as well as pharmaceutical compositions containing it and its use in the treatment of gastrointestinal disorders.</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>The patent claims omeprazole sodium form B.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p> <p>Omeprazole is available in generic form.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
101	F. Hoffmann-La Roche	EP 99119179.3 13.9.1999	2000/1160 12.9.2000 Pub Date. 6/2008	24225 10.11.2008	11.9.2020	<i>Solid Lipid Formulations</i> The present invention refers to a pharmaceutical composition comprising at least one inhibitor of lipases and at least one fatty acid ester of polyols, characterized in that the fatty acid ester has a melting point above the body temperature and the polyols are chosen from the group consisting of sugars, sugar derivatives and mixtures thereof.	<i>Patent Type: Product (Composition)</i> This patent claims a pharmaceutical composition comprising at least one inhibitor of lipases (orlistat) and at least one fatty acid ester of polyols, characterized in that the fatty acid ester has a melting point above the body temperature and the polyols are chosen from the group consisting of glycerol, sugars, sugar derivatives and mixtures thereof. Orlistat is marketed as Xenical to help with weight loss. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.
102	Astra Zeneca AB	GB 9922271.3. 21.9.1999	2000/1205 20.9.2000 Pub Date. 6/2008	24226 10.11.2008	19.9.2020	<i>Formulation</i> Granule formulation of quetiapine and pharmaceutically acceptable salt thereof are described, as are their preparation and their use in treating diseases of the central nervous system such as psychotic disease conditions including schizophrenia.	<i>Patent Type: Product (Formulation)</i> This patent claims a granule formulation comprising quetiapine fumarate. Quetiapine fumarate is marketed as Seroquel, for treating schizophrenia. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.



	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
103	Boehringer Ingelheim Pharma KG	DE 10126924.2 10.6.2001	2002/0570 29.5.2002 Pub Date. 6/2008	24227 10.11.2008	28.5.2022	<p><i>Capsule for inhalation</i></p> <p>The invention relates to capsules for inhalation (inhalettes) made from specific capsule materials with a reduced moisture content, which contain the active substance tiotropium in the form of powdered preparations and are characterised by increased stability.</p>	<p><i>Patent Type: Product (Formulation)</i></p> <p>This patent covers inhalation capsules containing tiotropium bromide.</p> <p>Tiotropium bromide is marketed as Spiriva for treating chronic obstructive pulmonary disease.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>
104	Pfizer Products Inc	US 60/290861 14.5.2001	2002/0483 13.5.2002 Pub Date. 6/2008	24228 10.11.2008	12.5.2022	<p><i>Tartrate salts of 5,8,18-triazatetracyclo[010.3.1.0.0]hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof</i></p> <p>The present invention is directed to the tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene of formula (1), and pharmaceutical compositions thereof. The present invention in particular is directed to the L-tartrate salt, and further to the various polymorphs of the L-tartrate salt, including two distinct anhydrous polymorphs (referred to herein as Forms A and B) and a hydrate polymorph (referred to herein as Form</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent claims the tartrate salt of varenicline.</p> <p>This patent relates to the marketed product Chantix, used to aid smoking cessation.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						<p>C). In addition, the present invention is also directed to the D-tartrate salt of 5,8,14-triazatetracyclo[10.3.1.0_{2,11}.0_{4,9}]-hexadeca-2(11),3,5,7,9-pentaene and the various polymorphs thereof; as well as the D,L-tartrate salt thereof and its polymorphs, and the meso-tartrate salt thereof and its polymorphs.</p> 	
105	Pfizer Inc	US 08/413300 30.3.1995 IB PCT/IB 95/00436 6.6.1995	1996/0269 28.3.1996 Pub Date. 6/2008	24229 10.11.2008	27.3.2016	<p><i>Quinazoline derivatives</i></p> <p>The invention relates to certain 4-(substitutedphenylamino)quinazoline derivatives of formula (I), their produgs and pharmaceutically acceptable salts wherein R<1>, R<2>, R<3>, R<4>, m and n are described in said formula. The compounds of formula (I), their produgs and pharmaceutically acceptable salts are useful for the treatment of hyperproliferative diseases.</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent covers the various quinazoline derivatives, including the compound erlotinib.</p> <p>This patent relates to the marketed product Tarceva used to treat non-small cell lung cancer.</p>


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
							
106	Astra Aktiebolag	SE 9702065.5 30.5.1997	0580/1998 27.5.1998 Pub Date. 7/2008	24291 8.1.2009	26.5.2018	<p><i>Novel form of s-omepra-zole</i></p> <p>The present invention relates to a novel form of the (-)-enantiomer of 5-methoxy-2- [[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent covers the S-enantiomer of omeprazole, known as S-omeprazole. Specifically it claims the magnesium salt of the S-enantiomer of omeprazole trihydrate (esomeprazole).</p> <p>This patent relates to the marketed product Vimovo for treating osteoarthritis.</p>
107	F.Hoffman-La Roche	US 60/018834 31.5.1996	0465/1997 27.5.1997 Pub Date. 7/2008	24292 8.1.2009	26.5.2017	<p><i>Interferon conjugates</i></p> <p>Physiologically active PEG-IFN alpha conjugates having a formula as follows:</p>	<p><i>Patent Type: Product/Biological (Formulation of a Protein)</i></p> <p>This patent covers a pegylated interferon conjugate derivatives of the protein interferon alpha 2a.</p>



	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
							This patent relates to the marketed product Pegasys, used to treat hepatitis C.
108	F.Hoffman-La Roche	EP 0117918.3 21.8.2000	0906/2001 20.8.2001 Pub Date. 7/2008	24293 8.1.2009	19.8.2021	<p><i>Prodrugs to NMDA receptor ligands</i></p> <p>The invention relates to compounds of the general formula (I) wherein R is a) -C(O)(CH₂)_nC(O)OH, b) wherein R₁ is -N(R₂)(R₃) and R₂/R₃ are independently from each other hydrogen or lower alkyl, or is a cyclic tertiary amine, optionally substituted by lower alkyl, c) -P(O)(OH)₂, or is d) -C(O)(CH₂)_nNHC(O)(CH₂)_nN(R₂)(R₃); and n is 1, 2, 3 or 4; and to pharmaceutically acceptable acid addition salts thereof. These compounds may be used as prodrugs for the parent compound of formula (II) which are useful in the treatment of NMDA receptor-related diseases.</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent covers prodrugs of N-Methyl-D aspartate (NMDA) receptor subtype selective blockers useful in modulating neuronal activity for learning and memory function.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>
109	F.Hoffman-La Roche	US 08/468493 6.6.1995	0508/1996 6.6.1996	24294 8.1.2009	5.6.2016	<p><i>Pharmaceutical compositions</i></p> <p>Compositions which increase the bioavailability of proteinase</p>	<p><i>Patent Type: Product (Formulation)</i></p> <p>This patent claims a unit dose pharmaceutical formulation comprising</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
			Pub Date. 7/2008			inhibitors are disclosed. Compositions which include a pharmaceutically acceptable carrier comprising monoglycerides of medium chain-fatty acids.	saquinavir. This patent relates to the marketed product Fortovase, for treating HIV.
110	Advanced Renal Technologies	US 60/105049 20.10.1998 US 09/176063 20.10.1998	1296/1999 18.10.1999 Pub Date. 7/2008	24303 12.1.2009	17.10.2019	<i>Buffered compositions for dialysis</i> Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.	<i>Patent Type: Product (Composition)</i> This patent claims a dialysate precursor composition. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.
111	Menarini Ricerche S.P.A	IT FI2001A000203 29.10.2001 IT FI2002A000104 14.6.2002	1138/2002 19.10.2002 Pub Date. 9/2008	24335 1.2.2009	18.10.2022	<i>Linear basic compounds having NK-2 antagonist activity and formulations thereof</i> Described herein are compounds of formula (I) useful as antagonists of tachykinins in general, and in particular of neurokinin A; and the pharmaceutical formulations comprising the compounds of formula (I).	<i>Patent Type: Product (Compounds)</i> This patent covers non peptidic compounds. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
							
112	Warner Lambert Company		1608/1998 26.12.1998 Pub Date. 6/1008	24355 4.3.2009	25.12.2018	<p><i>Gaba analogs and their use in preventing and treating gastrointestinal damage</i></p> <p>GABA analogs are useful to prevent and treat gastrointestinal damage and ethanol withdrawal syndrome . Perferred treatments employ gabapentin or pregabalin.</p>	Information not available
113	Eli Lilly and Co	US 60/296350 6.6.2001	0594/2002 4.6.2002 Pub Date. 9/2008	24356 4.3.2009	3.6.2022	<p><i>Antitumor compounds and methods</i></p> <p>The present invention provides antitumor compounds of the formula(I), and antitumor methods.</p> 	<p><i>Patent Type: Product (Compound)</i></p> <p>The patent claims benzoylsulfonamides and sulfonylbenzamides for use as anti-tumour agents.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
114	F. Hoffmann-La Roche	EP 001163930 28.7.2000	0821/2001 28.7.2001 Pub Date. 9/2008	24357 4.3.2009	27.7.2021	<i>New Pharmaceutical composition</i> The present invention relates to pharmaceutical combination compositions, compositions and methods for treating obesity. More particularly, the invention relates to a combination or composition comprising a lipase inhibitor, preferably orlistat and a bile acid sequestrant.	<i>Patent Type: Product (Composition)</i> This patent covers pharmaceutical composition comprising orlistat useful for treating obesity. Orlistat is marketed under the name Alli by Roche. This patent is not listed under the US FDA Orange Book for orlistat.
115	F. Hoffmann-La Roche	US 60/255273 13.12.2000 60/318715 13.9.2001	1316/2001 10.12.2001 Pub Date. 9/2008	24358 4.3.2009	9.12.2021	<i>Isoindolin-1-one glucokinase activators</i> Isoindolin -1- one - substituted propionamide glucokinase activators which increase insulin secretion in the treatment of type II diabetes .	<i>Patent Type: Product (Compound)</i> This patent covers Isoindolin -1- one - substituted propionamide glucokinase activators which increase insulin secretion in the treatment of type II diabetes. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.
116	F. Hoffmann-La Roche	US 60/169089 6.12.1999	1502/2000 3.12.2000 Pub Date. 9/2008	24361 4.3.2009	2.12.2020	<i>4-pyrimiding1-n-acyl.l.phenalanines</i> Compounds of Formula (I) are disclosed, wherein R<1> to R<6> are as defined in specification and which are inhibitors of binding between VCAM-1 and cells expressing VLA-4, and accordingly are useful for	<i>Patent Type: Product (Compound)</i> This patent covers 4-pyrimiding1-n-acyl.l.phenalanines compounds, which may be useful as agents for treatment of chronic inflammatory diseases e.g. rheumatoid arthritis, asthma and multiple sclerosis. This patent does not appear to relate to a


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						<p>treating diseases whose symptoms and or damage are related to the binding of VCAM-1 to cells expressing VLA-4.</p>  <p>(I)</p>	marketed product as listed on the US FDA Orange Book.
117	The Procter & Gamble Company	US 60/323625 20.9.2001	1037/2002 21.9.2002 Pub Date. 9/2008	24363 4.3.2009	20.9.2022	<p><i>6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines</i></p> <p>The present invention relates to compound which are capable of preventing the extracellular release of inflammatory cytokines, said compounds, including all enantiomeric and diastereomeric forms and pharmaceutically acceptable salts thereof, have the formula I:</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent covers bicyclic pyrazolones and derivatives (including anatiomeric and diastereomeric forms) useful as mediators in many disease areas including, arthritis, osteoarthritis, inflammatory bowel disease (IBS), septic shock, cardiopulmonary dysfunction, acute respiratory disease and cachexia.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						 (I)	
118	UCB SA	UK 0004297.8 23.2.2000	0172/2001 21.2.2001 Pub Date. 8/2008	24375 19.3.2009	20.2.2021	<p><i>2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses</i></p> <p>The invention concerns 2-oxo-1-pyrrolidine derivatives of formula (I):</p>  (I) <p>wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the invention are</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent covers analogs of the compound levetiracetam, useful in the treatment of epilepsy.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						particularly suited for treating neurological disorders such as epilepsy.	
119	American Cynamid Company	US 60/247100 10.11.2000 US 60/3330345 18.10.2001	1183/2001 10.11.2001 Pub Date. 10/2008	24378 26.3.2009	9.11.2021	<i>Adjuvant combination formulations</i> The use of an aminoalkyl glucosamine phosphate compound, or a derivative or analog thereof, in combination with a cytokine or lymphokine such as granulocyte macrophage colony stimulating factor or interleukin-12, is useful as an adjuvant combination in an antigenic composition to enhance the immune response in a vertebrate host to a selected antigen.	<i>Patent Type: Product (Composition)</i> This patent covers aminoalkyl glucosamine phosphate compound (AGP), or a derivative or analog thereof, combined with a cytokine or lymphokine, in particular granulocyte-macrophage colony stimulating factor. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.
120	Merck Frosst Canada Co	US 60/339549 26.10.2001	1164/2002 23.10.2002 Pub Date. 11/2008	24380 5.4.2009	22.10.2022	<i>Granule formulation</i> The present invention relates to oral granules of montelukast sodium.	<i>Patent Type: Product (Formulation)</i> This patent covers oral granules of montelukast sodium. Montelukast sodium is marketed under the trade names Singulair and Montelo-10 for use in the treatment of asthma and seasonal allergies. This patent is not listed on the US FDA Orange book for Singulair.


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
121	Merck & Co Inc	US 60/160356 19.10.1999	1342/2000 21.10.2000 Pub Date.11/2008	24381 5.4.2009	20.10.2020	<i>Tyrosine kinase inhibitors</i> The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.	<i>Patent Type: Product (Compound)</i> This patent covers tyrosine kinase inhibitors useful for treating angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.
122	LG Chem Investment Ltd	KP 2001/3087 19.1.2001	0063/2002 19.1.2002 Pub Date. 11/2008	24382 5.4.2009	18.1.2022	<i>Novel cyclic nucleoside phosphonate derivatives, salts thereof and process for preparation of the same</i> The present invention relates to an acyclic nucleoside phosphonate derivative, which is useful as an antiviral agent (particularly, against hepatitis B virus), pharmaceutically acceptable salts, stereoisomers, and a process for the preparation thereof.	<i>Patent Type: Product (Compound)</i> The present invention relates to an acyclic nucleoside phosphonate derivative, which is useful as an antiviral agent (particularly, against hepatitis B virus). This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.
123	Laboratoires Jacques Logeais	FR 98/03155 13.3.1998	0261/1999 13.3.1999 Pub Date. 2/2009	24397 27.4.2009	12.3.2019	<i>Salts of keto acids and amine derivatives and their use for the preparation of medicaments</i>	Information not available

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						A natural amino acid particularly an amino acid chosen from ornithine, arginine, lysine, histidine or glutamine represents a keto acid corresponding to formula below r-co-cooh in which r represents ch3-ch2 ch3 ch (ch3)2 ch2-ch3 -ch2 -ch (ch3)2 (ch3)2 cooh-ch2)3 cooh z represents a natural amino acid particularly an amino acid chosen from ornithin arginine lysine histidine or glutamine or apolyamine chosen particularly from cadaverine putrescine spermidine spermine or a agmatine for the preparation o a medicament intended for the treatment of pathological conditions in humans or animals involving painless neurons such as pathological conditions of the digestive tract bladder and biliary tract.	
124	Pfizer Products Inc	US 60/170179 10.12.1999	1516/2000 6.12.2000 Pub Date. 11/2008	24399 29.4.2009	25.2.2020	<i>Pyrrolo[2,3-D]pyrimidine compounds</i> A compound of formula (I):	<i>Patent Type: Product (Compound)</i> The present invention relates to pyrrolo [2, 3-d] pyrimidine compounds which are inhibitors of protein kinases, such as the enzyme Janus Kinase 3 (hereinafter also referred to as JAK3) and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis,

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						 <p>(I)</p> <p>wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplantation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.</p>	psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other indications where immunosuppression would be desirable.
125	Pfizer Inc	GB 9828420.1 23.12.1998 GB 9921375.3 10.9.1999	1592/1999 14.12.1999 Pub Date. 11/2008	24400 29.4.2009	13.12.2019	<p><i>CCR5 Modulators</i></p> <p>Compounds of the Formula (I) [Region alpha] - [Region beta] - [Region gamma] - [Region delta] which are useful as modulators of chemokine activity. The invention</p>	<p><i>Patent Type :Product (Compound)</i></p> <p>This patent claims azabicycloalkanes as CCR5 modulators for treating inflammatory diseases and the treatment/prevention of HIV-1.</p>


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						also provides pharmaceutical formulations and methods of treatment using these compounds.	This patent relates to the marketed product Selzentry (maraviroc) for treating HIV/AIDS.
126	Pfizer Inc	US 60/016537 7.5.1996	0377/1997 4.5.1997 Pub Date. 11/2008	24401 29.4.2009	3.5.2017	<i>Mesylate. Trihydrate of 5-(2-(4-(1,2-benzisothiazole-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-ine</i> The invention relates to the mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one, pharmaceutical compositions containing said mesylate trihydrate salt, and methods of using said mesylate trihydrate salt to treat psychotic disorders.	<i>Patent Type: Product (Salt of Compound)</i> This patent claims the mesylate trihydrate salt of ziprasidone. The patent relates to the marketed product Geodon, for treating psychotic diseases.
127	Novartis AG	US 60/361515 4.3.2002 US 60/409275 9.9.2002	0208/2003 2.3.2003 Pub Date. 11/2008	24403 29.4.2009	1.3.2023	<i>Ophthalmic Composition</i> This invention relates to topical ophthalmic compositions comprising an ascomycin e.g. for the treatment of inflammatory diseases such as blepharitis.	<i>Patent Type: Product (Composition)</i> This patent covers a composition comprising ascomycin for treatment of inflammatory diseases such as blepharitis. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.
128	Bayer Corporation		0039/2000 15.1.2000	24407 20.5.2009	14.1.2020	<i>Carboxyaryl substituted diphenyl</i>	<i>Patent Type: Product (Compound)</i> This patent covers the compound sorafenib,

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
			Pub Date. 12/2008			<p><i>ureas as raf kinase inhibitors</i></p> <p>This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.</p>	<p>an anti-cancer drug.</p> <p>The patent relates to the marketed product Nexavar.</p>
129	Bristol Myers Squibb Co	US 60/185672 29.2.2000 US 60/221313 28.7.2000	0191/2001 26.2.2001 Pub Date. 12/2008	24408 20.5.2009	25.2.2021	<p><i>Low dose entecavir formulation and use</i></p> <p>Compositions containing a low dose of entecavir are administered on a daily basis to treat hepatitis B virus infection and/or co-infections. Formulations for the oral administration of a low dose of entecavir are provided. Other pharmaceutically active substances can be included in the entecavir composition or can be separately administered for the treatment of hepatitis B virus infection or for the treatment of co-infected patients.</p>	<p><i>Patent Type: Product (Composition)</i></p> <p>This patent covers a composition comprising entecavir, useful for treating hepatitis B.</p> <p>Entecavir is marketed under the trade name Baraclude. This patent is not listed on the US FDA Orange Book for the Baraclude.</p>
130	Bristol Myers Squibb Co	US 09/727957 1.12.2000 US 09/746060	0550/2001 23.5.2001 Pub Date. 12/2008	24409 20.5.2009	22.5.2021	<p><i>N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitors of</i></p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent claims protein kinase inhibitors useful in the treatment cancer, inflammation arthritis, Alzheimers disease and</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
		22.12.2000 US 09/616627 26.7.2000				<p><i>cyclin dependent kinases</i></p> <p>The present invention describes compounds of the formula (I) and enantiomers, diastereomers, solvates, and pharmaceutically acceptable salts thereof. The formula I compounds are protein kinase inhibitors and are useful in the treatment of proliferative diseases, for example, cancer, inflammation and arthritis . They may also be useful in the treatment of Alzheimer's disease, chemotherapy-induced alopecia, and cardiovascular diseases.</p>	<p>cardiovascular disease.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>
131	Pfizer Inc	GB 9924063.2 11.1.1999 GB 0018656 28.7.2000	1281/2000 9.10.2000 Pub Date. 12/2008	24411 25.5.2009	8.10.2020	<p><i>Pharmaceutically active compounds</i></p> <p>Compounds of formula (I):</p>  <p>wherein R1, R2, R4 and R13 are as defined or a pharmaceutically or veterinarily acceptable salt or</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent claims a series of pyrazolo [4,3-d] pyrimidin-7-ones compounds which have utility in a variety of therapeutic areas, in particular for the treatment of sexual dysfunctions.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						polymorph thereof, or a pharmaceutically or veterinarily acceptable solvate or pro-drug thereof: are potent and selective inhibitors of type 5 cyclic guanosine 3', 5'-monophosphate phosphodiesterase (cGMP PDE5) and have utility in the treatment of, inter alia, male erectile dysfunction (MED) and female sexual dysfunction (FSD).	
132	Astra Pharmaceutica ls Ltd	SE 9702773.4 22.7.1997 SE 9702775.9 22.7.1997	0864/1998 22.7.1998 12/2008	24412 25.5.2009	21.7.2018	<i>Novel compounds</i> The invention provides new triazolo[4,5-d]pyrimidine compounds of formula (I), their use as medicaments, compositions containing them and processes for their preparation.	<i>Patent Type: Product (Compound)</i> This patent claims triazolo[4,5-d]pyrimidine derivative compounds useful as thrombin inhibitors. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.
133	The Proctor & Gamble Company	US 60/323625 20.9.2001	1039/2002 21.9.2002 Pub Date. 12/2008	24413 25.5.2009	20.9.2022	<i>Compound which inhibit the release of inflammatory cytokines</i> The present invention relates to compounds which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions comprising said	<i>Patent Type: Product (Compound)</i> This patent claims bicyclic pyrazolones and derivatives effective for inhibiting release of inflammatory cytokines. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						compounds and method for preventing abating, or otherwise controlling enzymes which are understood to be the active components responsible for the herein described disease states .	
134	Astra Aktiebolag	SE 9604793.1.20 20.12.1996	1360/19997 20.12.1997 Pub Date. 12/2008	24414 25.5.2009	19.12.2017	<i>A novel compound form</i> The invention provides S-omeprazole in a neutral form characterised in that it is in a solid state, preferably in a partly crystalline or substantially crystalline state, such as form A or form B. Furthermore, the invention provides processes for the preparation of S-omeprazole and its use in medicine.	<i>Patent Type: Product (Compound)</i> This patent claims a neutral form of the S-enantiomer of omeprazole and process for its preparation. Omeprazole is used to treat gastroesophageal reflux disease (GERD) and is available in generic form as well as the branded version Nexium (S-omeprazole) sold by AstraZeneca.
135	Novartis AG	EP 02005117.3 7.3.2002 EP 02005115.7 7.3.2002	0215/2003 3.3.2003 Pub Date. 12/2008	24415 25.5.2009	2.3.2023	<i>Quinoline derivatives</i> The present invention relates to novel benzo [g] quinoline derivatives, their preparation, their use as pharmaceuticals for use in the treatment of glaucoma and myopia.	<i>Patent Type: Product (Compound)</i> This patent covers quinoline derivative compounds. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
136	Pfizer Products Inc	US 60/168217 30.11.1999	1477/2000 27.11.2000 Pub Date. 1/2009	24433 25.6.2009	26.11.2020	<p><i>Novel benzimidazole derivatives useful as antiproliferative agents</i></p> <p>The invention relates to compounds of formula (1):</p>  <p style="text-align: right;">(1)</p> <p>and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1, R7, R8, R9, R10, and R11 are as defined herein. The invention also relates to methods of treating abnormal cell growth, such as cancer, in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula (1). The invention also relates to methods of preparing the compounds of formula (1).</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>The patent claims benzimidazole derivatives useful in the treating cancer.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
137	Astra Aktiebolag	SE 9402924.6 2.9.1994 SE 9402925.3 2.9.1994	0732/1995 31.8.1995 Pub Date. 1/2009	24435 25.6.2009	30.8.2015	<i>Novel pharmaceutical composition</i> A pharmaceutical composition which is a combination of the ACE inhibitor ramipril and a calcium antagonist of one of the dihydropyridine type compounds felodipine, nitrendipine, nifedipine and lacidipine. The pharmaceutical composition is for use in the therapy and treatment of hypertension.	<i>Patent Type: Product (Composition/Combination)</i> This patent covers a preparation for oral administration comprising a combination of an ACE inhibitor ramipril and a dihydropyridine compound selected from felodipine, nitrendipine, nifedipine, and lacidipine, useful in the therapy of hypertension and cardiovascular diseases. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book. *NB The combination of ramipril and felodipine was under clinical trial by Sanofi-Aventis. It is not clear if the product was approved and if this patent relates to the Sanofi product.
138	Berwind Pharmaceutical Services Inc	US 09/351076 9.7.1999	0866/2000 2.7.2000 Pub Date. 1/2009	24436 25.6.2009	1.7.2020	<i>Film coatings and film coating compositions based on polyvinyl alcohol</i> A dry film coating composition for use in coating pharmaceutical tablets, nutritional supplements, food, confectionery forms, agricultural seeds, and the like, comprises	<i>Patent Type: Product (Composition)</i> This patent relates to a dry film coating composition for use in coating pharmaceutical tablets, nutritional supplements, food and confectionery forms. This patent does not appear to relate to a marketed product as listed on the US


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						polyvinyl alcohol, a plasticizer such as polyethylene glycol or glycerin, talc, and preferably a pigment/opacifier and lecithin. A method of coating substrates such as pharmaceutical tablets, nutritional supplements, food, confectionery forms, agricultural seeds, and the like, with a film coating, comprises the steps of mixing polyvinyl alcohol, a plasticizer such as polyethylene glycol or glycerin, talc, and preferably a pigment/opacifier and lecithin into water to form an aqueous coating dispersion, applying an effective amount of said coating dispersion onto said substrates to form a film coating on said substrates, and drying the film coating on said substrates.	FDA Orange Book.
139	Bristol Myers Squibb Co	US 09/579927 26.5.2000 US 60/214065 26.6.2000	0548/2001 23.5.2001 Pub Date. 2/2009	24459 16.7.2009	22.5.2021	<i>Soluble CTLA4 mutant molecules and uses thereof</i> The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular	<i>Patent Type: Product (Compound)</i> This patent covers CTLA4 mutant molecules. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.	
140	Janssen Pharmaceutica NV	EP 00202180.6 22.6.2000	0661/2001 20.6.2001 Pub Date. 2/2009	24462 16.7.2009	19.6.2009	<p><i>Compounds for treating fundic disaccomodation</i></p> <p>The present invention is concernmed with novel componds having fundic relaxation properties. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine of said compounds to restore disturbed fundic accommodation. Processes for preparing siad products formulation comprising said products and their use as a medicine are disclosed in particular for treating conditons which are related to disturbed fundic accommodation.</p>	<p>Patent Type: <i>Product (Compound)</i></p> <p>This patent covers derivatives of benzodioxane, benzofuran or benzopyran compounds, having fundic relaxation properties.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>
141	Smithkline Beecham Plc Smithkline	GB 9824870.1 12.11.1998	1429/1999 11.11.1999	24463 16.7.2009	10.11.2019	<p><i>Modified release pharmaceutical composition</i></p> <p>A pharmaceutical composition which</p>	<p>Patent Type: <i>Product (Composition)</i></p> <p>This patent covers a pharmaceutical composition comprising an insulin sensitiser</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
	Beecham Corporation	GB 9912189.9 25.5.1999	Pub Date. 2/2009			composition comprises an insulin sensitiser and a pharmaceutically acceptable carrier therefor, wherein the composition is arranged to provide a modified release of the insulin sensitiser and the use of such composition in medicine.	(pioglitazone or troglitazone) and a pharmaceutical acceptable carrier. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.
142	Bristol Myers Squibb Co	US 60/051951 8.7.1997 US 60/067524 4.12.1997	0792/1998 7.7.1998 Pub Date. 2/2009	24464 16.7.2009	6.7.2018	<i>Epothilone derivatives</i> The present invention relates to compounds of formula (I), Q is selected from the group consisting of (II), G is selected from the group consisting of alkyl, substituted alkyl, substituted or or unsubstituted aryl, heterocyclo, (III), W is O or NR15; X is O or H,H; Y is selected from the group consisting of O; H,OR16; OR17,OR17; NOR18; H,NOR19; H,NR20R21; H,H; or CHR22; OR17OR17 can be a cyclic ketal; Z1 and Z2 are selected from the group consisting of CH2, O, NR23, S or SO2, wherein only one of Z and Z2 is a heteroatom; B1 and B2 are selected from the group consisting of OR24, or OCOR25, or 2CNR26R27; when B1 is H and Y is OH, H they can form a six-membered ring ketal or acetal; D is selected from the group	Patent Type: Product (Compound) This patent relates to epothilone derivative compounds. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						<p>consisting of NR28R29, NR30COR31 or saturated heterocycle R1, R2, R3, R4, R5, R6, R7, R13, R14, R18, R19, R20, R21, R22, R26 and R27 are selected from the group H, alkyl, substituted alkyl, or aryl and when R1 and R2 are alkyl can be joined to form a cycloalkyl; R3 and R4 are alkyl can be joined to form a cycloalkyl; R9, R10, R16, R17, R24, R25, and R31 are selected from the group H, alkyl, or substituted alkyl; R8, R11, R12, R28, R30, R32, R33, and R30 are selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, or heterocyclo; R15, R23 and R29 are selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, heterocyclo, R32C=O, R33SO2, hydroxy, O-alkyl or O-substituted alkyl, the pharmaceutically acceptable salts thereof and any hydrates, solvates or geometric, optical and stereoisomers thereof, with the proviso that compounds wherein: W and X are both O; and R1, R2, R7 are H; and R3, R4, R6, are methyl; and R8, is H or methyl; and Z1, and Z2, are CH2;</p>	

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						and G is 1-methyl-2-(substituted-4-thiazolyl)ethenyl; and Q is as defined above are excluded.	
143	Merck & Co Inc Isis Pharmaceutica ls Inc	US 60/263313 22.1.2001 US 60/282069 6.4.2001 US 60/299320 19.6.2001 US 60/344528 25.10.2001	0072/2002 21.1.2002 Pub Date. 2/2009	24465 27.7.2009	20.1.2022	<p><i>Nucleoside derivatives as inhibitors of RNA dependent RNA viral polymerase</i></p> <p>The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase,</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent covers nucleoside derivatives useful as inhibitors of hepatitis C.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.	
144	Boehringer Ingelheim Pharma	DE 10050635.6 12.10.2000 DE 10138022.4 10.8.2001	1063/2001 10.10.2001 Pub Date. 2/2009	24478 3.8.2009	9.10.2021	<i>New inhalable powder containing tiotropium</i> The invention relates to a novel method for producing powdery preparations for inhalation	<i>Patent Type: Method/Process</i> This patent covers a method for the production of powders for inhalation including tiotropium.
145	Astrazeneca AB		1045/2003 22.11.2003 Pub Date. 2/2009	24479 3.8.2009	21.11.2023	<i>Modified release pharmaceutical formulation</i> A modified release pharmaceutical composition comprising, as active ingredient, a compound of formula (I):  (I)	<i>Patent Type: Product (Composition)</i> This patent covers a modified release pharmaceutical composition. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						hydroxy, methoxy or ethoxy; andn represents 0, 1 or 2; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable diluent or carrier; provided that the formulation may only contain iota-carrageenan and a neutral gelling polymer when the compound of formula (I) is in the form of a salt; such formulations being of use for the treatment of a cardiovascular disorder.	
146	Duch-Esnay Inc	CA 2350195 21.6.2001	0693/2002 19.6.2002 Pub Date. 3/2009	24483 9.8.2009	18.6.2022	<i>Rapid Onset Formulation</i> Provided herein is a novel enterically-coated pyridoxine HCl and doxylamine succinate rapid onset formulation comprising a disintegrating agent such that the following dissolution profiles are satisfied when measured in 1000 ml phosphate buffer at pH 6.8 and 37 DEG C. in a type 2 dissolution apparatus at 100 rpm:(a) at least about 40% of the total pyridoxine HCl and doxylamine succinate is dissolved after 30 minutes of measurement; (b) at least about 70% of the total pyridoxine HCl and doxylamine succinate is dissolved	<i>Patent Type: Product (Formulation)</i> This patent covers a rapid onset formulation, preferably in form of an enterically coated tablet, for a medicament comprising a synergistic duo of active ingredients namely, doxylamine succinate and pyridoxine HCl. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						after 60 minutes of measurement; (c) at least about 80% of the total pyridoxine HCl and doxylamine succinate is dissolved after 90 minutes of measurement; (d) at about 90% of the total pyridoxine HCl and doxylamine succinate is dissolved after 120 minutes of measurement. Preferably the formulation will contain a core coated with at least one enteric coating, the core comprising pyridoxine HCl, doxylamine succinate and the following non-active excipients: a filler or binder, a disintegrating agent, a lubricant, a silica flow conditioner and a stabilizing agent.	
147	Chiesi Farmaceutica SPA	GB 0211753.9 22.5.2002	0468/2003 19.5.2003 Pub Date. 2/2009	24425 14.6.2009	18.5.2023	<i>Drug delivery assembly</i> This invention relates to a drug delivery assembly which includes a pressurised container (10) holding a drug formulation with a propellant, the container being disposed within a sealed enclosure (12) forming an overwrap or secondary packaging comprising a gas adsorbing material consisting of a microporous zeolite having a pore opening size less than 20 Å.	<i>Patent Type: Product (Container for holding formulations)</i> This patent covers a drug delivery assembly, comprising formoterol. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
148	Bristol Myers Squibb Co	US 60/158773 12.10.1999 US 60/194615 5.4.2000	1279/2000 9.10.2000 Pub Date. 3/2009	24515 19.8.2009	8.10.2020	<p><i>C</i>-aryl glucoside SGLT2 inhibitors and method</p> <p>SGLT2 inhibiting compounds are provided having formula (I):</p>  <p>(I)</p> <p>where R1, R2, and R2a are independently hydrogen, OH, OR5, lower alkyl, CF3, OCHF2, OCF3, SR5i or halogen, or two of R1, R2 and R2a together with the carbons to which they are attached can form an annelated five, six or seven membered carbocycle or heterocycle; R3 and R4 are independently hydrogen, OH, OR5a, OAryl, OCH2Aryl, lower alkyl, cycloalkyl, CF3, -OCHF2, -OCF3, halogen, -CN, -CO2R<5b>, -CO2H, -COR6b, -CH(OH)R6c, -CH(OR5h)R6d, -CONR6R6a, -NHCOR<5c>, -NHSO2R5d, -NHSO2Aryl, Aryl, -</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent covers C-aryl glucosides which are inhibitors of sodium dependent glucose transporters found in the intestine and kidney (SGLT2) and to a method for treating diabetes, especially type II diabetes, as well as hyperglycemia, hyperinsulinemia, obesity and hypertriglyceridemia.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						SR5e, -SOR5f, SO2R5g, SO2Aryl, or a five, six or seven membered heterocycle, or R3 and R4 together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle; R5, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h, and R5I are independently lower alkyl; R6, R6a, R6b, R6c and R6d are independently hydrogen, alkyl, aryl, alkylaryl or cycloalkyl, or R6 and R6a together with the nitrogen to which they are attached form an annelated five, six or seven membered heterocycle; A is O, S, NH, or (CH2)n where n is 0 - 3. A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.	
149	Smithkline Beecham Corporation	US 60/272570 1.3.2001	0473/2003 20.5.2003 Pub Date. 3/2009	24516 19.8.2009	19.5.2023	<i>Peptide deformylase inhibitors</i> Nobel PDF inhibitors and novel methods for their use are provided.	<i>Patent Type: Product (Compound)</i> This patent covers polypeptide deformylase compounds. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
150	Schering Corporation	US 09/305187 4.5.1999	0563/2000 2.5.2000 Pub Date. 3/2009	24533 30.8.2009	1.5.2020	<p><i>Piperidine derivatives useful as CCR5 antagonists</i></p> <p>The use of CCR5 antagonists of formula (I) or a pharmaceutically acceptable salt thereof, wherein X is -C(R13)2-, -C(R13)(R19)-, -C(O)-, -O-, -NH-, -N(alkyl)-, (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m) or (n); R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is H, alkyl or alkenyl; R2 is optionally substituted phenyl, phenylalkyl, heteroaryl or heteroarylalkyl, naphthyl, fluorenyl or diphenylmethyl; R3 is optionally substituted phenyl, heteroaryl or naphthyl; R4 is H, alkyl, fluoro-alkyl, cyclopropylmethyl, -CH2CH2OH, -CH2CH2-O-alkyl, -CH2C(O)-O-alkyl, -CH2C(O)NH2, -CH2C(O)-NHalkyl or -CH2C(O)-N(alkyl)2; R19 is optionally substituted phenyl, heteroaryl or naphthyl, cycloalkyl, cycloalkylalkyl or alkoxyalkyl; and R5, R13, R14, R15 and R16 are hydrogen or alkyl for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis,</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent claims piperidine derivatives useful as selective CCR5 antagonists and for treating HIV and in combination with another agent to treat solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.	
151	Astra Aktiebolag	SE 9402510.3 15.7.1994	0571/1995 11.7.1995 Pub Date. 3/2009	24534 30.8.2009	10.7.2015	<p><i>Process for synthesis of substituted sulfoxides</i></p> <p>A novel process for enantioselective synthesis of single enantiomers of omeprazole or its alkaline salts, of other optically pure substituted 2-(2-pyridinylmethyl-sulphinyl)-1H-benzimidazoles as well as of other structurally related sulfoxides or their alkaline salts. The claimed process is an asymmetric oxidation of a pro-chiral sulphide to the single enantiomers or an enantiomerically enriched form of the corresponding sulphoxide. The application also claims the enantiomeric sulphoxide products produced by the process and</p>	<p><i>Patent Type: Process</i></p> <p>This patent claims a process for synthesising omeprazole.</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						their use in medicine.	
152	Boehringer Ingelheim Pharma KG	DE 10233500.1 24.7.2002	0712/2003 22.7.2003 Pub Date. 5/2009	24562 25.10.2009	21.7.2003	<p><i>3-Z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition</i></p> <p>The present invention relates to the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate of formula (I) and the use thereof as a pharmaceutical composition.</p>  <p style="text-align: right;">(I)</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent covers crystalline forms of indoline derivatives.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>
153	Ferring BV	US 60/328831 15.10.2001 DK PCT/DK01006	1118/2002 14.10.2002 Pub Date. 7/2009	24584 16.11.2009	13.10.2022	<p><i>Method for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of uicerative colitis</i></p>	Information not available


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
		77 15.10.2001				<p><i>and crohn's disease</i></p> <p>The present invention concerns a new method of preparing granules comprising 5- aminosalicylic acid and a new method of preparing a pharmaceutical composition for the treatment of ulcerative colitis or crohn' s disease by oral administration comprising as active ingredient 5- aminosalicylic acid.</p>	
154	Eli Lilly and Co	US 60/026884 23.9.1996	0981/1997 23.9.1997 Pub Date. 10/2009	24660 7.4.2010	22.9.2017	<p><i>Pharmaceutical composition of olanzapine and fluoxetine for treatment of psychoses</i></p> <p>The invention relates to "pharmacological composition of olanzapine and fluoxetine for treatment of psychoses" .</p>	<p><i>Patent Type: Method of Use/Treatment</i></p> <p>This patent claims a method for treating a patient suffering from or susceptible to psychosis, acute mania, mild anxiety states, or depression by administering in combination a component selected from olanzapine, clozapine, risperidone, sertindole, quetiapine, and ziprasidone; and the second component is selected from the group consisting of fluoxetine, venlafaxine, citalopram, fluvoxamine, paroxetine, sertraline, milnacipran and duloxetine.</p> <p>Olanzapine and fluoxetine is marketed by Eli Lilly under the trade name Symbax.</p> <p>This patent does not appear to relate to a marketed product as listed on the US</p>


	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
							FDA Orange Book.
155	Pfizer Products Inc	US 06/421874 28.10.2002	1003/2003 27.10.2003 Pub Date. 10/2009	24662 7.4.2010	26.10.2023	<p><i>Purine compounds and uses thereof</i></p> <p>Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.</p> 	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent covers purine compounds and intermediates useful as cannabinoid ligands.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>
156	Bristol Myers Squibb Co	US 60/184004 22.2.2000	0152/2001 19.2.2001 Pub Date. 10/2009	24669 11.4.2010	18.2.2021	<p><i>Antiviral azaindole derivatives</i></p> <p>The present invention is directed to a series of chemical entities that express HIV-1 inhibitory activities.</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent covers azaindole piperazine diamide derivatives, useful for treating HIV/AIDS.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>
157	Mendes S.U.R.L	IT RM99A00376	0749/2000	24675	6.6.2020	<p><i>Composition comprising alkaline sphingomyelinase for use a dietetic</i></p>	<p><i>Patent Type: Product (Composition)</i></p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
		9.6.1999	7.6.2000 Pub Date. 11/2009	27.4.2010		<p><i>preparation food supplement or pharmaceutical product</i></p> <p>The invention relates to a composition which, depending on the user, may be taken as a nutritional, dietetic or strictly therapeutic preparation, comprising as its active substance alkaline sphingomyelinase which is capable of preventing or treating various pathological conditions including cancerous processes, inflammatory processes of the intestine, hypercholesterolaemia and infections with <i>Helicobacter pylori</i>.</p>	<p>This patent covers a composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement.</p> <p>This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.</p>
158	Pfizer Inc	US 60/057276 29.8.1997	1025/1998 27.8.1998 Pub Date. 11/2009	24678 27.4.2010	26.8.2018	<p>Combination therapy</p> <p>This invention relates to pharmaceutical combinations of atorvastatin or a pharmaceutically acceptable salt thereof and antihypertensive agents, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac</p>	<p><i>Patent Type: Product (Composition)</i></p> <p>This patent covers a composition comprising atorvastatin, an antihypertensive agent (calcium channel blocker, an ACE inhibitor, an All antagonist, a diuretic, a beta-adrenergic receptor blocker or an alpha-adrenergic receptor blocker) and a pharmaceutical acceptable carrier.</p> <p>Atorvastatin is marketed as Lipitor.</p> <p>This patent appears to relates to a combination that does not appear to</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						risk, including humans. This invention also relates to additive and synergistic combinations of atorvastatin or a pharmaceutically acceptable salt thereof and antihypertensive agents whereby those synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms of cardiac risk, including humans.	relate to a marketed product as listed on the US FDA Orange Book.
159	Janssen Pharmaceutic a N.V.	EP 98204347.3 19.12.1998	1626/1999 18.12.1999 Pub Date. 7/2009	24605 10.1.2010	17.12.2019	<i>Antihistaminic spiro compounds</i> his invention concerns the compounds of formula (I) a prodrug, a N-oxide, an addition salt, a quaternary amine or a stereochemically isomeric form thereof wherein R1 is hydrogen, C1-6alkyl, halo, formyl, carboxyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyl, N(R3R4)C(=O)-, N(R3R4)C(=O)N(R5)-, ethenyl substituted with carboxyl or C1-6alkyloxycarbonyl, or C1-6alkyl substituted with hydroxy, carboxyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, N(R3R4)C(=O)-, C1-6alkylC(=O)N(R5)-, C1-	<i>Patent Type: Product (Compound)</i> This patent covers spiro compounds with antihistaminic activity. This patent does not appear to relate to a marketed product as listed on the US FDA Orange Book.

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						<p>6alkylS(=O)₂N(R₅)- or N(R₃R₄)C(=O)N(R₅)- wherein each R₃ and each R₄ independently are hydrogen or C1-4alkyl, and R₅ is hydrogen or hydroxy; R₂ is hydrogen, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, N(R₃R₄)C(=O)-, aryl or halo; n is 1 or 2; -A-B- represents a bivalent radical of formula -Y-CH=CH-, -CH=CH-Y-, or -CH=CH-CH=CH-, wherein each hydrogen atom may independently be replaced by R₆ wherein R₆ is C1-6alkyl, halo, hydroxy, C1-6alkyloxy, ethenyl substituted with carboxyl or C1-6alkyloxycarbonyl, hydroxyC1-6alkyl, formyl, carboxyl or hydroxycarbonylC1-6alkyl, and each Y independently is a bivalent radical of formula -O-, -S- or -NR₇-, wherein R₇ is hydrogen, C1-6alkyl or C1-6alkylcarbonyl; Z is a bivalent radical of formula -(CH₂)_p-, -CH=CH-, -CH₂-CHOH-, -CH₂-O-, -CH₂-C(=O), or -CH₂-C(=NOH)-, provided that the bivalent radicals are connected to the nitrogen of the imidazole ring via their -CH₂-moiety; and wherein p is 1, 2, 3 or 4; L is hydrogen; C1-6alkyl; C2-</p>	

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						<p>6alkenyl; C1-6alkylcarbonyl; C1-6alkyloxycarbonyl; C1-6alkyl substituted with hydroxy, carboxyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, aryl, aryloxy, cyano or R⁸HN- wherein R⁸ is hydrogen, C1-6alkyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyl; or L represents a radical of formula -Alk-Y-Het1, -Alk-NH-CO-Het2 or -Alk-Het3 wherein Alk represents C1-4alkanediyl; Y represents O, S or NH; Het1, Het2 and Het3 each represent an optionally substituted heterocycle; for use as a medicine.</p>  <p style="text-align: center;">(I)</p>	
160	Janssen Pharmaceutica N.V	EP 0123090.4 13.8.2001 EP 02077748.8	0892/2002 10.8.2002 Pub Date. 11/2009	24684 5.5.2010	9.8.2022	<p><i>HIV replication inhibiting pyrimidines</i></p> <p>This invention concerns HIV replication inhibitors of formula (I) the N -oxides, the pharmaceutically</p>	<p><i>Patent Type: Product (Compound)</i></p> <p>This patent covers pyrimidine derivatives with HIV replication inhibiting properties.</p> <p>This patent does not appear to relate to a</p>

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
		10.6.2002				<p>acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, wherein the ring containing - a1=a2-a3=a5- and -b1=b2b3=b4 e1,r2,r3,r4 as disclosed in the specification.</p> 	marketed product as listed on the US FDA Orange Book.
161	Medical Union Pharmaceuticals		0498/2001 13.5.2001 Pub Date. 12/2009	24704 27.5.2010	12.5.2021	<p><i>A method for the preparation of stable pharmaceutical compositions for intramuscular injection, combining folic acid with other vitamins in a single aqueous solution</i></p> <p>The method involves the solubilization of folic acid-in presence of other vitamins- in an acidic medium fuH a.5 - 6) by reducing suitable amounts of pharmaceutically acceptable di- and/or tri-hydric alcohols and/or by reducing the surface tension of the vehicle to 35-50 mN/m by suitable amounts of non-ionic surfactants. Pharmaceutically acceptable chelating agents may be added to</p>	Information not available

	Applicant	Priority No(s)	Application No./Date Publication Date	Patent No./ Grant Date	Expected Expiry	Title/Abstract	Patent Type/Subject Matter/ Product/Treatment Category - Based on Corresponding European/PCT/US Patent Claims
						enhance the stability pharmacologically active substances as local anesthetics as local anesthetics may be added to enhance the acceptability. The oxygen in the solution is displaced by nitrogen and the solution is sterile - filtered .	